Comprehensive Physiology Wiley Online Library
For Librarians For Authors Editors About

Hypothalamic‐Pituitary‐Adrenocortical Axis: Neuropsychiatric Aspects

Lauren Jacobson

10.1002/cphy.c130036

Source: Volume 4, Issue 2, April 2014

Published online: March 2014

Full Article on Wiley Online Library



Abstract

Evidence of aberrant hypothalamic‐pituitary‐adrenocortical (HPA) activity in many psychiatric disorders, although not universal, has sparked long‐standing interest in HPA hormones as biomarkers of disease or treatment response. HPA activity may be chronically elevated in melancholic depression, panic disorder, obsessive‐compulsive disorder, and schizophrenia. The HPA axis may be more reactive to stress in social anxiety disorder and autism spectrum disorders. In contrast, HPA activity is more likely to be low in PTSD and atypical depression. Antidepressants are widely considered to inhibit HPA activity, although inhibition is not unanimously reported in the literature. There is evidence, also uneven, that the mood stabilizers lithium and carbamazepine have the potential to augment HPA measures, while benzodiazepines, atypical antipsychotics, and to some extent, typical antipsychotics have the potential to inhibit HPA activity. Currently, the most reliable use of HPA measures in most disorders is to predict the likelihood of relapse, although changes in HPA activity have also been proposed to play a role in the clinical benefits of psychiatric treatments. Greater attention to patient heterogeneity and more consistent approaches to assessing treatment effects on HPA function may solidify the value of HPA measures in predicting treatment response or developing novel strategies to manage psychiatric disease. © 2014 American Physiological Society. Compr Physiol 4:715‐738, 2014.

References
 1. Abelson JL , Curtis GC . Hypothalamic‐pituitary‐adrenal axis activity in panic disorder: Prediction of long‐term outcome by pretreatment cortisol levels. Am J Psychiatry 153: 69‐73, 1996a.
 2. Abelson JL , Curtis GC . Hypothalamic‐pituitary‐adrenal axis activity in panic disorder. 24‐hour secretion of corticotropin and cortisol. Arch Gen Psychiatry 53: 323‐331, 1996b.
 3. Abelson JL , Curtis GC , Cameron OG . Hypothalamic‐pituitary‐adrenal axis activity in panic disorder: Effects of alprazolam on 24 h secretion of adrenocorticotropin and cortisol. J Psychiatr Res 30: 79‐93, 1996.
 4. Abelson JL , Khan S , Liberzon I , Young EA . HPA axis activity in patients with panic disorder: Review and synthesis of four studies. Depress Anxiety 24: 66‐76, 2007.
 5. Adli M , Bschor T , Bauer M , Lucka C , Lewitzka U , Ising M , Uhr M , Mueller‐Oerlinghausen B , Baethge C . Long‐term outcome after lithium augmentation in unipolar depression: Focus on HPA system activity. Neuropsychobiology 60: 23‐30, 2009.
 6. Aerni A , Traber R , Hock C , Roozendaal B , Schelling G , Papassotiropoulos A , Nitsch RM , Schnyder U , deQuervain DJ . Low‐dose cortisol for symptoms of posttraumatic stress disorder. Am J Psychiatry 161: 1488‐1490, 2004.
 7. Alevizos B , Hatzimanolis J , Markianos M , Stefanis CN . Clinical, endocrine and neurochemical effects of moclobemide in depressed patients. Acta Psychiatr Scand 87: 285‐290, 1993.
 8. Altemus M , Pigott T , Kalogeras KT , Demitrack M , Dubbert B , Murphy DL , Gold PW . Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive‐compulsive disorder. Arch Gen Psychiatry 49: 9‐20, 1992.
 9. Ambrosi F , Ricci S , Quartesan R , Moretti P , Pelicci G , Pagliacci C , Nicoletti I . Effects of acute benzodiazepine administration on growth hormone, prolactin and cortisol release after moderate insulin‐induced hypoglycemia in normal women. Psychopharmacology 88: 187‐189, 1986.
 10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders IV (4th ed). Washington, D.C.: American Psychiatric Association, 2000.
 11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders V (5th ed). Arlington, VA: American Psychiatric Publishing, 2013.
 12. Amsterdam JD , Maislin G , Droba M , Winokur A . The ACTH stimulation test before and after clinical recovery from depression. Psychiatry Res 20: 325‐336, 1987.
 13. Anderson CJ , Colombo J , Unruh KE . Pupil and salivary indicators of autonomic dysfunction in autism spectrum disorder. Dev Psychobiol 55: 465‐482, 2013.
 14. Andrews JM , Nemeroff CB . Contemporary management of depression. Am J Med 97(Suppl 6A): 24S‐32S, 1994.
 15. Anisman H , Ravindran AV , Griffiths J , Merali Z . Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 4: 182‐188, 1999.
 16. Arana GW , Baldessarini RJ , Ornsteen M . The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review. Arch Gen Psychiatry 42: 1193‐1204, 1985.
 17. Arana GW , Santos AB , Laraia MT , McLeod‐Bryant S , Beale MD , Rames LJ , Roberts JM , Dias JK , Molloy M . Dexamethasone for the treatment of depression: A randomized, placebo‐controlled, double‐blind trial. Am J Psychiatry 152: 265‐267, 1995.
 18. Araya AV , Rojas P , Fritsch R , Rojas R , Herrera L , Rojas G , Gatica H , Silva H , Fiedler JL . Early response to venlafaxine antidepressant correlates with lower ACTH levels prior to pharmacological treatment. Endocrine 30: 289‐298, 2006.
 19. Arvat E , Giordano R , Grottoli S , Ghigo E . Benzodiazepines and anterior pituitary function. J Endocrinol Invest 25: 735‐747, 2002.
 20. Asnis GM , Kohn SR , Brown NL . SSRIs versus non‐SSRIs in post‐traumatic stress disorder: An update with recommendations. Drugs 64: 383‐404, 2004.
 21. Balbo M , Leproult R , Van Cauter E . Impact of sleep and its disturbances on hypothalamo‐pituitary‐adrenal axis activity. Int J Endocrinol 2010: ID 759234, 759231‐759216, 2010.
 22. Bale TL , Vale WW . CRF and CRF receptors: Role in stress responsivity and other behaviors. Ann Rev Pharmacol Toxicol 44: 525‐557, 2004.
 23. Banasr M , Dwyer JM , Duman RS . Cell atrophy and loss in depression: Reversal by antidepressant treatment. Curr Opin Cell Biol 23: 730‐737, 2011.
 24. Bandelow B , Wedekind D , Sandvoss V , Broocks A , Hajak G , Pauls J , Peter H , Rüther E . Diurnal variation of cortisol in panic disorder. Psychiatry Res 95: 245‐250, 2000.
 25. Banki CM , Bissette G , Arato M , O'Connor L , Nemeroff CB . CSF corticotropin‐releasing factor‐like immunoreactivity in depression and schizophrenia. Am J Psychiatry 144: 873‐877, 1987.
 26. Banki CM , Karmacsi L , Bissette G , Nemeroff CB . CSF corticotropin‐releasing hormone and somatostatin in major depression: Response to antidepressant treatment and relapse. Eur Neuropsychopharmacol 2: 107‐113, 1992.
 27. Baptista T , Alastre T , Contreras Q , Martinez JL , Araujo de Baptista E , Burguera JL , de Burguera M , Hernández L . Effects of lithium carbonate on reproductive hormones in healthy men: Relationship with body weight regulation–a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 21: 937‐950, 1997.
 28. Baptista T , Lacruz A , de Mendoza S , Guillén M , Burguera JL , de Burguera M , Hernández L . Endocrine effects of lithium carbonate in healthy premenopausal women: Relationship with body weight regulation. Prog Neuropsychopharmacol Biol Psychiatry 24: 1‐16, 2000.
 29. Belgorodsky A , Knyazhansky L , Loewenthal U , Arbelle J , Cohen H , Benjamin J . Effects of the cortisol synthesis inhibitor metyrapone on the response to carbon dioxide challenge in panic disorder. Depress Anxiety 21: 143‐148, 2005.
 30. Benedetti MS . Enzyme induction and inhibition by new antiepileptic drugs: A review of human studies. Fundam Clin Pharmacol 14: 301‐319, 2000.
 31. Berlin I , Warot D , Legout V , Guillemant S , Schöllnhammer G , Puech AJ . Blunted 5‐HT1A‐receptor agonist‐induced corticotropin and cortisol responses after long‐term ipsapirone and fluoxetine administration to healthy subjects. Clin Pharmacol Ther 63: 428‐436, 1998.
 32. Bick PA . Obsessive‐compulsive behavior associated with dexamethasone treatment. J Nerv Ment Dis 171: 253‐254, 1983.
 33. Binneman B , Feltner D , Kolluri S , Shi Y , Qiu R , Stiger T . A 6‐week randomized, placebo‐controlled trial of CP‐316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 165: 617‐620, 2008.
 34. Blasey CM , Block TS , Belanoff JK , Roe RL . Efficacy and safety of mifepristone for the treatment of psychotic depression. J Clin Psychopharmacol 31: 436‐440, 2011.
 35. Bonne O , Gill JM , Luckenbaugh DA , Collins C , Owens MJ , Alesci S , Neumeister A , Yuan P , Kinkead B , Manji HK , Charney DS , Vythilingam M . Corticotropin‐releasing factor, interleukin‐6, brain‐derived neurotrophic factor, insulin‐like growth factor‐1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. J Clin Psychiatry 72: 1124‐1128, 2011.
 36. Bourgon LN , Kellner CH . Relapse of depression after ECT: A review. J ECT 16: 19‐31, 2000.
 37. Bouwer C , Claassen J , Dinan TG , Nemeroff CB . Prednisone augmentation in treatment‐resistant depression with fatigue and hypocortisolaemia: A case series. Depress Anxiety 12: 44‐50, 2000.
 38. Bowden CL , Perlis RH , Thase ME , Ketter TA , Ostacher MM , Calabrese JR , Reilly‐Harrington NA , Gonzalez JM , Singh V , Nierenberg AA , Sachs GS . Aims and results of the NIMH systematic treatment enhancement program for bipolar disorder (STEP‐BD). CNS Neurosci Ther 18: 243‐249, 2012.
 39. Bradley AJ , Dinan TG . A systematic review of hypothalamic‐pituitary‐adrenal axis function in schizophrenia: Implications for mortality. J Psychopharmacol 24(Suppl 4): 91‐118, 2010.
 40. Brady KT , Killeen TK , Brewerton T , Lucerini S . Comorbidity of psychiatric disorders and posttraumatic stress disorder. J Clin Psychiatry 61(Suppl 7): 22‐32, 2000.
 41. Brambilla F , Bellodi L , Perna G , Arancio C , Bertani A , Perini G , Carraro C , Gava F . Noradrenergic receptor sensitivity in obsessive compulsive disorder: II. Cortisol response to acute clonidine administration. Psychiatry Res 69: 163‐168, 1997.
 42. Brambilla F , Guerrini A , Guastalla A , Rovere C , Riggi F . Neuroendocrine effects of haloperidol therapy in chronic schizophrenia. Psychopharmacologia 44: 17‐22, 1975.
 43. Brawman‐Mintzer O , Lydiard RB . Biological basis of generalized anxiety disorder. J Clin Psychiatry 58(Suppl 3): 16‐25, 1997.
 44. Breier A , Davis OR , Buchanan RW . Alprazolam attenuates metabolic stress‐induced neuroendocrine and behavioral effects in humans. Psychopharmacology 104: 479‐484, 1991.
 45. Breier A , Buchanan RW , Waltrip 2nd RW , Listwak S , Holmes C , Goldstein DS . The effect of clozapine on plasma norepinephrine: Relationship to clinical efficacy. Neuropsychopharmacology 10: 1‐7, 1994.
 46. Breier A , Charney DS , Heninger GR . Intravenous diazepam fails to change growth hormone and cortisol secretion in humans. Psychiatry Res 18: 293‐299, 1986.
 47. Bremner D , Vermetten E , Kelley ME . Cortisol, dehydroepiandrosterone, and estradiol measured over 24 hours in women with childhood sexual abuse‐related posttraumatic stress disorder. J Nerv Ment Dis 195: 919‐927, 2007.
 48. Brenner K , Liu A , Laplante DP , Lupien S , Pruessner JC , Ciampi A , Joober R , King S . Cortisol response to a psychosocial stressor in schizophrenia: Blunted, delayed, or normal? Psychoneuroendocrinology 34: 859‐868, 2009.
 49. Brosnan M , Turner‐Cobb J , Munro‐Naan Z , Jessop D . Absence of a normal cortisol awakening response (CAR) in adolescent males with Asperger syndrome (AS). Psychoneuroendocrinology 34: 1095‐1100, 2009.
 50. Brown ES . Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann N Y Acad Sci 1179: 41‐55, 2009.
 51. Brunelin J , d'Amato T , van Os J , Cochet A , Suaud‐Chagny MF , Saoud M . Effects of acute metabolic stress on the dopaminergic and pituitary‐adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls. Schizophr Res 100: 206‐211, 2008.
 52. Bschor T , Ritter D , Winkelmann P , Erbe S , Uhr M , Ising M , Lewitzka U . Lithium monotherapy increases ACTH and cortisol response in the DEX/CRH test in unipolar depressed subjects. A study with 30 treatment‐naive patients. PLoS One 6: e27613. doi:27610.21371/journal.pone.0027613, 2011.
 53. Calfa G , Kademian S , Ceschin D , Vega G , Rabinovich GA , Volosin M . Characterization and functional significance of glucocorticoid receptors in patients with major depression: Modulation by antidepressant treatment. Psychoneuroendocrinology 28: 687‐701, 2003.
 54. Cameron OG , Nesse RM . Systemic hormonal and physiological abnormalities in anxiety disorders. Psychoneuroendocrinology 13: 287‐307, 1988.
 55. Cansu A , Serdaroglu A , Cinaz P . Serum insulin, cortisol, leptin, neuropeptide Y, galanin and ghrelin levels in epileptic children receiving oxcarbazepine. Eur J Paediatr Neurol 15: 527‐531, 2011.
 56. Carpenter LL , Tyrka AR , Lee JK , Tracy AP , Wilkinson CW , Price LH . A placebo‐controlled study of sertraline's effect on cortisol response to the dexamethasone/corticotropin‐releasing hormone test in healthy adults. Psychopharmacology 218: 371‐379, 2011.
 57. Carroll BJ , Martin FI , Davies B . Resistance to suppression by dexamethasone of plasma 11‐O.H.C.S. levels in severe depressive illness. Br Med J 3: 285‐287, 1968.
 58. Carroll BJ . Hypothalamic–pituitary function in depressive illness: Insensitivity to hypoglycaemia. Br Med J 3: 27‐28, 1969.
 59. Carroll BJ , Feinberg M , Greden JF , Tarika J , Albala AA , Haskett RF , James NM , Kronfol Z , Lohr N , Steiner M , de Vigne JP , Young E . A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 38: 15‐22, 1981.
 60. Casolini P , Kabbaj M , Piazza PV , Angelucci L , Simon H , LeMoal M , Maccari S . The D1 agonist SKF 38393, but not the D2 agonist LY 171555, decreases the affinity of type II corticosteroid receptors in rat hippocampus and ventral striatum. Neuroscience 60: 939‐943, 1994.
 61. Casper RC , Kocsis J , Dysken M , Stokes P , Croughan J , Maas J . Cortisol measures in primary major depressive disorder with hypersomnia or appetite increase. J Affective Disorders 15: 131‐140, 1988.
 62. Catapano F , Monteleone P , Maj M , Kemali D . Dexamethasone suppression test in patients with primary obsessive‐compulsive disorder and in healthy controls. Neuropsychobiology 23: 53‐56, 1990.
 63. Cervantes P , Gelber S , Kin FN , Nair VN , Schwartz G . Circadian secretion of cortisol in bipolar disorder. J Psychiatry Neurosci 26: 411‐416, 2001.
 64. Charney DS , Goodman WK , Price LH , Woods SW , Rasmussen SA , Heninger GR . Serotonin function in obsessive‐compulsive disorder. A comparison of the effects of tryptophan and m‐chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry 45: 177‐185, 1988.
 65. Chopra KK , Ravindran A , Kennedy SH , Mackenzie B , Matthews S , Anisman H , Bagby RM , Farvolden P , Levitan RD . Sex differences in hormonal responses to a social stressor in chronic major depression. Psychoneuroendocrinology 34: 1235‐1241, 2009.
 66. Clayton PJ . Depression subtyping: Treatment implications. J Clin Psychiatry 59: 5‐12; discussion 40‐12, 1998.
 67. Cohn JB , Wilcox CS , Meltzer HY . Neuroendocrine effects of buspirone in patients with generalized anxiety disorder. Am J Med 80: 36‐40, 1986.
 68. Cohrs S , Pohlmann K , Guan Z , Jordan W , Meier A , Huether G , Rüther E , Rodenbeck A . Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects. Psychopharmacology 174: 414‐420, 2004.
 69. Cohrs S , Röher C , Jordan W , Meier A , Huether G , Wuttke W , Rüther E , Rodenbeck A . The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology 185: 11‐18, 2006.
 70. Coiro V , Volpi R , Casti A , Maffei ML , Stella A , Volta E , Chiodera P . Naloxone decreases the inhibitory effect of alprazolam on the release of adrenocorticotropin/cortisol induced by physical exercise in man. Br J Clin Pharmacol 71: 951‐955, 2011.
 71. Condren RM , O'Neill A , Ryan MC , Barrett P , Thakore JH . HPA axis response to a psychological stressor in generalised social phobia. Psychoneuroendocrinology 27: 693‐703, 2002.
 72. Connolly KR , Thase ME . Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs 17: 105‐126, 2012.
 73. Contreras F , Menchon JM , Urretavizcaya M , Navarro MA , Vallejo J , Parker G . Hormonal differences between psychotic and non‐psychotic melancholic depression. J Affect Disord 100: 65‐73, 2007.
 74. Cook EH . Autism: Review of neurochemical investigation. Synapse 6: 292‐308, 1990.
 75. Cookson JC , Silverstone T , Williams S , Besser GM . Plasma cortisol levels in mania: Associated clinical ratings and changes during treatment with haloperidol. Br J Psychiatry 146: 498‐502, 1985.
 76. Coplan JD , Goetz R , Klein DF , Papp LA , Fyer AJ , Liebowitz MR , Davies SO , Gorman JM . Plasma cortisol concentrations preceding lactate‐induced panic. Psychological, biochemical, and physiological correlates. Arch Gen Psychiatry 55: 130‐136, 1998.
 77. Corbett BA , Mendoza S , Abdullah M , Wegelin JA , Levine S . Cortisol circadian rhythms and response to stress in children with autism. Psychoneuroendocrinology 31: 59‐68, 2006.
 78. Corbett BA , Schupp CW , Lanni KE . Comparing biobehavioral profiles across two social stress paradigms in children with and without autism spectrum disorders. Mol Autism 3: 13. doi: 10.1186/2040‐2392‐1183‐1113, 2012.
 79. Coric V , Feldman HH , Oren DA , Shekhar A , Pultz J , Dockens RC , Wu X , Gentile KA , Huang SP , Emison E , Delmonte T , D'Souza BB , Zimbroff DL , Grebb JA , Goddard AW , Stock EG . Multicenter, randomized, double‐blind, active comparator and placebo‐controlled trial of a corticotropin‐releasing factor receptor‐1 antagonist in generalized anxiety disorder. Depress Anxiety 27: 417‐425, 2010.
 80. Coryell W , Noyes Jr R , Clancy J , Crowe R , Chaudhry D . Abnormal escape from dexamethasone suppression in agoraphobia with panic attacks. Psychiatry Res 15: 301‐311, 1985.
 81. Coryell W , Noyes Jr R , Schlechte J . The significance of HPA axis disturbance in panic disorder. Biol Psychiatry 25: 989‐1002, 1989.
 82. Coryell WH , Black DW , Kelly MW , Noyes Jr R . HPA axis disturbance in obsessive‐compulsive disorder. Psychiatry Res 30: 243‐251, 1989.
 83. Cromer KR , Schmidt NB , Murphy DL . An investigation of traumatic life events and obsessive‐compulsive disorder. Behav Res Ther 45: 1683‐1691, 2007.
 84. Curin JM , Terzić C , Petković ZB , Zekan L , Terzić M , Susnjara IM . Lower cortisol and higher ACTH levels in individuals with autism. J Autism Dev Disord 33: 443‐448, 2003.
 85. Curtis GC , Abelson JL , Gold PW . Adrenocorticotropic hormone and cortisol responses to corticotropin‐releasing hormone: Changes in panic disorder and effects of alprazolam treatment. Biol Psychiatry 41: 76‐85, 1997.
 86. Daban C , Vieta E , Mackin P , Young AH . Hypothalamic‐pituitary‐adrenal axis and bipolar disorder. Psychiatr Clin North Am 28: 469‐480, 2005.
 87. DeBattista C , Posener JA , Kalehzan BM , Schatzberg AF . Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: A double‐blind, placebo‐controlled study. Am J Psychiatry 157: 1334‐1337, 2000.
 88. DeBellis MD , Gold PW , Geracioti Jr TD , Listwak SJ , Kling MA . Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin‐releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 150: 656‐657, 1993.
 89. Dekker MJ , Tiemeier H , Luijendijk HJ , Kuningas M , Hofman A , de Jong FH , Stewart PM , Koper JW , Lamberts SW . The effect of common genetic variation in 11β‐hydroxysteroid dehydrogenase type 1 on hypothalamic‐pituitary‐adrenal axis activity and incident depression. J Clin Endocrinol Metab 97: E233‐237, 2012.
 90. de Kloet ER , Vreugdenhil E , Oitzl MS , Joels M . Brain corticosteroid receptor balance in health and disease. Endocrine Rev 19: 269‐301, 1998.
 91. de Koning P , de Vries MH . A comparison of the neuro‐endocrinological and temperature effects of DU 29894, flesinoxan, sulpiride and haloperidol in normal volunteers. Br J Clin Pharmacol 39: 7‐14, 1995.
 92. Demisch K , Demisch L , Bochnik HJ , Nickelsen T , Althoff PH , Schöffling K , Rieth R . Melatonin and cortisol increase after fluvoxamine. Br J Clin Pharmacol 22: 620‐622, 1986.
 93. de Quervain DJ , Aerni A , Schelling G , Roozendaal B . Glucocorticoids and the regulation of memory in health and disease. Front Neuroendocrinol 30: 358‐370, 2009.
 94. de Quervain DJ , Bentz D , Michael T , Bolt OC , Wiederhold BK , Margraf J , Wilhelm FH . Glucocorticoids enhance extinction‐based psychotherapy. Proc Natl Acad Sci USA 108: 6621‐6625, 2011.
 95. Desborough JP , Hall GM , Hart GR , Burrin JM . Midazolam modifies pancreatic and anterior pituitary hormone secretion during upper abdominal surgery. Br J Anaesth 67: 390‐396, 1991.
 96. Deshauer D , Grof E , Alda M , Grof P . Patterns of DST positivity in remitted affective disorders. Biol Psychiatry 45: 1023‐1029, 1999.
 97. De Souza EB . Neuroendocrine effects of benzodiazepines. J Psychiatr Res 24(Suppl 2): 111‐119, 1990.
 98. Deuschle M , Schweiger U , Weber B , Gotthardt U , Korner A , Schmider J , Standhardt H , Lammers CH , Heuser I . Diurnal activity and pulsatility of the hypothalamus‐pituitary‐adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab 82: 234‐238, 1997.
 99. Deuschle M , Hamann B , Meichel C , Krumm B , Lederbogen F , Kniest A , Colla M , Heuser I . Antidepressive treatment with amitriptyline and paroxetine: Effects on saliva cortisol concentrations. J Clin Psychopharmacol 23: 201‐205, 2003.
 100. Deuster PA , Faraday MM , Chrousos GP , Poth MA . Effects of dehydroepiandrosterone and alprazolam on hypothalamic‐pituitary responses to exercise. J Clin Endocrinol Metab 90: 4777‐4783, 2005.
 101. Di S , Malcher‐Lopes R , Halmos KC , Tasker JG . Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: A fast feedback mechanism. J Neurosci 23: 4850‐4857, 2003.
 102. Dinan TG , Lavelle E , Cooney J , Burnett F , Scott L , Dash A , Thakore J , Berti C . Dexamethasone augmentation in treatment‐resistant depression. Acta Psychiatr Scand 95: 58‐61, 1997.
 103. Dohanics J , Kovacs KJ , Makara GB . Oxytocinergic neurons in rat hypothalamus: Dexamethasone‐reversible increases in their corticotropin‐releasing factor 1‐41 immunoreactivity in response to osmotic stimulation. Neuroendocrinology 51: 515‐522, 1990.
 104. Edmondson D , Cohen BE . Posttraumatic stress disorder and cardiovascular disease. Prog Cardiovasc Dis 55: 548‐556, 2013.
 105. Elderon L , Whooley MA . Depression and cardiovascular disease. Prog Cardiovasc Dis 55: 511‐523, 2013.
 106. Ellenbogen MA , Santo JB , Linnen AM , Walker CD , Hodgins S . High cortisol levels in the offspring of parents with bipolar disorder during two weeks of daily sampling. Bipolar Disord 12: 77‐86, 2010.
 107. Ellenbogen MA , Hodgins S , Linnen AM , Ostiguy CS . Elevated daytime cortisol levels: A biomarker of subsequent major affective disorder? J Affect Disord 132: 265‐269, 2011.
 108. Elman I , Adler CM , Malhotra AK , Bir C , Pickar D , Breier A . Effect of acute metabolic stress on pituitary‐adrenal axis activation in patients with schizophrenia. Am J Psychiatry 155: 979‐981, 1998.
 109. Elzinga BM , Schmahl CG , Vermetten E , van Dyck R , Bremner JD . Higher cortisol levels following exposure to traumatic reminders in abuse‐related PTSD. Neuropsychopharmacology 28: 1656‐1665, 2003.
 110. Engeland WC , Arnhold MM . Neural circuitry in the regulation of adrenal corticosterone rhythmicity. Endocrine 28: 325‐332, 2005.
 111. Erhardt A , Ising M , Unschuld PG , Kern N , Lucae S , Pütz B , Uhr M , Binder EB , Holsboer F , Keck ME . Regulation of the hypothalamic‐pituitary‐adrenocortical system in patients with panic disorder. Neuropsychopharmacology 31: 2515‐2522, 2006.
 112. Ettigi PE , Goldberg SC , Schulz PM , Hamer RM , Blackard WG . Cortisol differentially predicts response to imipramine and alprazolam. Psychopharmacol Bull 24: 206‐209, 1988.
 113. Evanson NK , Herman JP , Sakai RR , Krause EG . Nongenomic actions of adrenal steroids in the central nervous system. J Neuroendocrinol 22: 846‐861, 2010.
 114. Farach FJ , Pruitt LD , Jun JJ , Jerud AB , Zoellner LA , Roy‐Byrne PP . Pharmacological treatment of anxiety disorders: Current treatments and future directions. J Anxiety Disord 26: 833‐843, 2012.
 115. Fawcett JA , Bunney Jr WE . Pituitary adrenal function and depression. Arch Gen Psychiatry 16: 517‐535, 1967.
 116. Field T , Diego M , Delgado J , Medina L . Peer support and interpersonal psychotherapy groups experienced decreased prenatal depression, anxiety and cortisol. Early Hum Dev 89: 621‐624, 2013.
 117. Fink G , Robinson IC , Tannahill LA . Effects of adrenalectomy and glucocorticoids on the peptides CRF‐41, AVP and oxytocin in rat hypophysial portal blood. J Physiol 401: 329‐345, 1988.
 118. Fleischhacker WW , Stuppäck C , Moser C , Schubert H , Hinterhuber H . Fluperlapine vs haloperidol: A comparison of their neuroendocrinological profiles and the influence on serum lipids. Pharmacopsychiatry 19: 111‐114, 1986.
 119. Flores BH , Kenna KH , Keller J , Solvason HB , Schatzberg AF . Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 31: 628‐636, 2006.
 120. Forman SD , Bissette G , Yao J , Nemeroff CB , van Kammen DP . Cerebrospinal fluid corticotropin‐releasing factor increases following haloperidol withdrawal in chronic schizophrenia. Schizophr Res 12: 43‐51, 1994.
 121. Fries E , Hellhammer DH , Hellhammer J . Attenuation of the hypothalamic‐pituitary‐adrenal axis responsivity to the Trier Social Stress Test by the benzodiazepine alprazolam. Psychoneuroendocrinology 31: 1278‐1288, 2006.
 122. Fritzsche A , Clamor A , von Leupoldt A . Effects of medical and psychological treatment of depression in patients with COPD–a review. Respir Med 105: 1422‐1433, 2011.
 123. Furlan PM , DeMartinis N , Schweizer E , Rickels K , Lucki I . Abnormal salivary cortisol levels in social phobic patients in response to acute psychological but not physical stress. Biol Psychiatry 50: 254‐259, 2001.
 124. Gabriels RL , Agnew JA , Pan Z , Holt KD , Reynolds A , Laudenslager ML . Elevated repetitive behaviors are associated with lower diurnal salivary cortisol levels in autism spectrum disorder. Biol Psychol 93: 262‐268, 2013.
 125. Gallagher P , Watson S , Smith MS , Ferrier IN , Young AH . Effects of adjunctive mifepristone (RU‐486) administration on neurocognitive function and symptoms in schizophrenia. Biol Psychiatry 57: 155‐161, 2005.
 126. Gallagher P , Malik N , Newham J , Young AH , Ferrier N , Mackin P . Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst Rev Jan 23(1): CD005168: doi: 10.1002/14651858.CD14005168.pub14651852, 2008.
 127. Garakani A , Martinez JM , Yehuda R , Gorman JM . Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment. J Affect Disord 146: 262‐265, 2013.
 128. Gasser PJ , Lowry CA , Orchinik M . Corticosterone‐sensitive monoamine transport in the rat dorsomedial hypothalamus: Potential role for organic cation transporter 3 in stress‐induced modulation of monoaminergic neurotransmission. J Neurosci 26: 8758‐8766, 2006.
 129. Geddes JR , Miklowitz DJ . Treatment of bipolar disorder. Lancet 381: 1672‐1682, 2013.
 130. Gehris TL , Kathol RG , Black DW , Noyes Jr R . Urinary free cortisol levels in obsessive‐compulsive disorder. Psychiatry Res 32: 151‐158, 1990.
 131. Geracioti TD , Loosen PT , Orth DN . Low cerebrospinal fluid corticotropin‐releasing hormone concentrations in eucortisolemic depression. Biol Psychiatry 42: 166‐174, 1997.
 132. Giordano R , Grottoli S , Brossa P , Pellegrino M , Destefanis S , Lanfranco F , Gianotti L , Ghigo A , Arvat E . Alprazolam (a benzodiazepine activating GABA receptor) reduces the neuroendocrine responses to insulin‐induced hypoglycaemia in humans. Clin Endocrinol 59: 314‐320, 2003.
 133. Gispen‐de Wied CC , Jansen LM , Duyx JH , Thijssen JH , van Engeland H . Pituitary‐adrenal function in adolescent psychiatric patients: Impact of depressive symptoms. J Affect Disord 59: 71‐76, 2000.
 134. Gola H , Engler H , Schauer M , Adenauer H , Riether C , Kolassa S , Elbert T , Kolassa IT . Victims of rape show increased cortisol responses to trauma reminders: A study in individuals with war‐ and torture‐related PTSD. Psychoneuroendocrinology 37: 213‐220, 2012.
 135. Gold PW , Chrousos GP . Organization of the stress system and its dysregulation in melancholic and atypical depression: High vs low CRH/NE states. Mol Psychiatry 7: 254‐275, 2002.
 136. Gold PW , Gabry KE , Yasuda M , Chrousos GP . Divergent endocrine abnormalities in melancholic and atypical depression: Clinical and pathophysiological implications. Endocrinol Metab Clin N Am 31: 37‐62, 2002.
 137. Goodwin GM , Muir WJ , Seckl JR , Bennie J , Carroll S , Dick H , Fink G . The effects of cortisol infusion upon hormone secretion from the anterior pituitary and subjective mood in depressive illness and in controls. J Affect Disord 26: 73‐83, 1992.
 138. Gourley SL , Wu FJ , Kiraly DD , Ploski JE , Kedves AT , Duman RS , Taylor JR . Regionally specific regulation of ERK MAP kinase in a model of antidepressant‐sensitive chronic depression. Biol Psychiatry 63: 353‐359, 2008.
 139. Graf EN , Wheeler RA , Baker DA , Ebben AL , Hill JE , McReynolds JR , Robble MA , Vranjkovic O , Wheeler DS , Mantsch JR , Gasser PJ . Corticosterone acts in the nucleus accumbens to enhance dopamine signaling and potentiate reinstatement of cocaine seeking. J Neurosci 33: 11800‐11810, 2013.
 140. Gram LF , Christensen P . Benzodiazepine suppression of cortisol secretion: A measure of anxiolytic activity? Pharmacopsychiatry 19: 19‐22, 1986.
 141. Greeves JA . Rapid‐onset steroid psychosis with very low dosage of prednisolone. Lancet 1: 1119‐1120, 1984.
 142. Grottoli S , Giordano R , Maccagno B , Pellegrino M , Ghigo E , Arvat E . The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus‐pituitary‐adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. J Clin Endocrinol Metab 87: 4616‐4620, 2002.
 143. Grottoli S , Maccagno B , Ramunni J , Di Vito L , Giordano R , Gianotti L , Destefanis S , Camanni F , Ghigo E , Arvat E . Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans. J Endocrinol Invest 25: 420‐425, 2002.
 144. Guest PC , Martins‐de‐Souza D , Vanattou‐Saifoudine N , Harris LW , Bahn S . Abnormalities in metabolism and hypothalamic‐pituitary‐adrenal axis function in schizophrenia. Int Rev Neurobiol 101: 145‐168, 2011.
 145. Guest PC , Schwarz E , Krishnamurthy D , Harris LW , Leweke FM , Rothermundt M , van Beveren NJ , Spain M , Barnes A , Steiner J , Rahmoune H , Bahn S . Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 36: 1092‐1096, 2011.
 146. Gustafsson PE , Gustafsson PA , Ivarsson T , Nelson N . Diurnal cortisol levels and cortisol response in youths with obsessive‐compulsive disorder. Neuropsychobiology 57: 14‐21, 2008.
 147. Gustavson SM , Sandoval DA , Ertl AC , Bao S , Raj SR , Davis SN . Stimulation of both type I and type II corticosteroid receptors blunts counterregulatory responses to subsequent hypoglycemia in healthy man. Am J Physiol 294: E506‐512, 2008.
 148. Halen NV , Cukor D , Constantiner M , Kimmel PL . Depression and mortality in end‐stage renal disease. Curr Psychiatry Rep 14: 36‐44, 2012.
 149. Hallam KT , Begg DP , Olver JS , Norman TR . An investigation of the effect of immediate and extended release venlafaxine on nocturnal melatonin and cortisol release in healthy adult volunteers. Hum Psychopharmacol 23: 129‐137, 2008.
 150. Handwerger K . Differential patterns of HPA activity and reactivity in adult posttraumatic stress disorder and major depressive disorder. Harv Rev Psychiatry 17: 184‐205, 2009.
 151. Harmer CJ , Bhagwagar Z , Shelley N , Cowen PJ . Contrasting effects of citalopram and reboxetine on waking salivary cortisol. Psychopharmacology 167: 112‐114, 2003.
 152. Harvard CWH , Saldanha VF , Bird R , Gardner R . The effect of diazepam on pituitary function in man. J Endocrinol 52: 79‐85, 1972.
 153. Hauger RL , Risbrough V , Oakley RH , Olivares‐Reyes JA , Dautzenberg FM . Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann N Y Acad Sci 1179: 120‐143, 2009.
 154. Heiske A , Jesberg J , Krieg J‐C , Vedder H . Differential effects of antidepressants on glucocorticoid receptors in human primary blood cells and human monocytic U‐937 cells. Neuropsychopharmacology 28: 807‐817, 2003.
 155. Hennig J , Rzepka U , Mai B , Netter P . Suppression of HPA‐axis activity by haloperidol after experimentally induced heat stress. Prog Neuropsychopharmacol Biol Psychiatry 19: 603‐614, 1995.
 156. Hennings JM , Owashi T , Binder EB , Horstmann S , Menke A , Kloiber S , Dose T , Wollweber B , Spieler D , Messer T , Lutz R , Künzel H , Bierner T , Pollmächer T , Pfister H , Nickel T , Sonntag A , Uhr M , Ising M , Holsboer F , Lucae S . Clinical characteristics and treatment outcome in a representative sample of depressed inpatients ‐ findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 43: 215‐229, 2009.
 157. Herman JP . Regulation of adrenocorticosteroid receptor mRNA expression in the central nervous system. Cell Molec Neurobiol 13: 349‐372, 1993.
 158. Hery M , Semont A , Fache MP , Faudon M , Hery F . The effects of serotonin on glucocorticoid receptor binding in rat raphe nuclei and hippocampal cells in culture. J Neurochem 74: 406‐413, 2000.
 159. Heuser I , Yassouridis A , Holsboer F . The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders. J Psychiatr Res 28: 341‐356, 1994.
 160. Heuser I , Bissette G , Dettling M , Schweiger U , Gotthardt U , Schmider J , Lammers CH , Nemeroff CB , Holsboer F . Cerebrospinal fluid concentrations of corticotropin‐releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: Response to amitriptyline treatment. Depress Anxiety 8: 71‐79, 1998.
 161. Heydendael W , Jacobson L . Differential effects of imipramine and phenelzine on corticosteroid receptor gene expression in mouse brain: Potential relevance to antidepressant response. Brain Research 1238: 93‐107, 2008.
 162. Heydendael W , Jacobson L . Glucocorticoid status affects antidepressant regulation of locus coeruleus tyrosine hydroxylase and dorsal raphé tryptophan hydroxylase gene expression. Brain Res 1288: 69‐78, 2009.
 163. Heydendael W , Jacobson L . Widespread hypothalamic‐pituitary‐adrenocortical axis‐relevant and mood‐relevant effects of chronic fluoxetine treatment on glucocorticoid receptor gene expression in mice. Eur J Neurosci 31: 892‐902, 2010.
 164. Hill MN , Ho W‐SV , Sinopoli KJ , Viau V , Hillard CJ , Gorzalka BB . Involvement of the endocannabinoid system in the ability of long‐term tricyclic antidepressant treatment to suppress stress‐induced activation of the hypothalamic‐pituitary‐adrenal axis. Neuropsychopharmacology 31: 2591‐2599, 2006.
 165. Hill MN , Barr AM , Ho W‐SV , Carrier EJ , Gorzalka BB , Hillard CJ . Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity. J Neurochem 103: 47‐56, 2007.
 166. Hill MN , Gorzalka BB . Impairments in endocannabinoid signaling and depressive illness. JAMA 301: 1165‐1166, 2009.
 167. Hill MN , Tasker JG . Endocannabinoid signaling, glucocorticoid‐mediated negative feedback, and regulation of the hypothalamic‐pituitary‐adrenal axis. Neuroscience 204: 5‐16, 2012.
 168. Hochberg Z , Pacak K , Chrousos GP . Endocrine withdrawal syndromes. Endocrine Rev 24: 523‐538, 2003.
 169. Hoehn T , Braune S , Scheibe G , Albus M . Physiological, biochemical and subjective parameters in anxiety patients with panic disorder during stress exposure as compared with healthy controls. Eur Arch Psychiatry Clin Neurosci 247: 264‐274, 1997.
 170. Hogler M , Wudy SA , Luef G , Hartmann MF , Rauchenzauner M . Oxcarbazepine accelerates cortisol elimination via cytochrome P450 3A4 induction. Arch Dis Child 95: 1065‐1067, 2010.
 171. Hollander E , DeCaria CM , Nitescu A , Gully R , Suckow RF , Cooper TB , Gorman JM , Klein DF , Liebowitz MR . Serotonergic function in obsessive‐compulsive disorder. Behavioral and neuroendocrine responses to oral m‐chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 49: 21‐28, 1992.
 172. Holsboer F , Liebl R , Hofschuster E . Repeated dexamethasone suppression test during depressive illness. Normalisation of test result compared with clinical improvement. J Affect Disord 4: 93‐101, 1982.
 173. Holsboer F . The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23: 477‐501, 2000.
 174. Holsboer F , Ising M . Central CRH system in depression and anxiety–evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 583: 350‐357, 2008.
 175. Hommer DW , Matsuo V , Wolkowitz O , Chrousos G , Greenblatt DJ , Weingartner H , Paul SM . Benzodiazepine sensitivity in normal human subjects. Arch Gen Psychiatry 43: 542‐551, 1986.
 176. Hood SD , Melichar JK , Taylor LG , Kalk N , Edwards TR , Hince DA , Lenox‐Smith A , Lingford‐Hughes AR , Nutt DJ . Noradrenergic function in generalized anxiety disorder: Impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge. J Psychopharmacol 25: 78‐86, 2011.
 177. Horstmann S , Binder EB . Glucocorticoids as predictors of treatment response in depression. Harv Rev Psychiatry 19: 125‐143, 2011.
 178. Hoshino Y , Ohno Y , Murata S , Yokoyama F , Kaneko M , Kumashiro H . Dexamethasone suppression test in autistic children. Folia Psychiatr Neurol Jpn 38: 445‐449, 1984.
 179. Huber GC , Fischer M , Mohr M , Agorastos A . Sudden worsening of Ross syndrome after glucocorticoid withdrawal emerges as panic disorder: A case report. J Neuropsychiatry Clin Neurosci 24: E28‐29, 2012.
 180. Hubert W , de Jong‐Meyer R . Saliva cortisol responses to unpleasant film stimuli differ between high and low trait anxious subjects. Neuropsychobiology 25: 115‐120, 1992.
 181. Inder WJ , Prickett TC , Mulder RT , Donald RA , Joyce PR . Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. Psychopharmacology 156: 73‐78, 2001.
 182. Insel T , Cuthbert B , Garvey M , Heinssen R , Pine DS , Quinn K , Sanislow C , Wang P . Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. Am J Psychiatry 167: 748‐751, 2010.
 183. Insel TR , Kalin NH , Guttmacher LB , Cohen RM , Murphy DL . The dexamethasone suppression test in patients with primary obsessive‐compulsive disorder. Psychiatry Res 6: 153‐160, 1982.
 184. Ising M , Kunzel HE , Binder EB , Nickel T , Modell S , Holsboer F . The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry 29: 1085‐1093, 2005.
 185. Ising M , Horstmann S , Kloiber S , Lucae S , Binder EB , Kern N , Künze HE , Pfennig A , Uhr M , Holsboer F . Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression ‐ a potential biomarker? Biol Psychiatry 62: 47‐54, 2007.
 186. Isojärvi JI . Serum steroid hormones and pituitary function in female epileptic patients during carbamazepine therapy. Epilepsia 31: 438‐445, 1990.
 187. Iwata K , Matsuzaki H , Miyachi T , Shimmura C , Suda S , Tsuchiya KJ , Matsumoto K , Suzuki K , Iwata Y , Nakamura K , Tsujii M , Sugiyama T , Sato K , Mori N . Investigation of the serum levels of anterior pituitary hormones in male children with autism. Mol Autism 2: 16, 2011.
 188. Jahn H , Schick M , Kiefer F , Kellner M , Yassouridis A , Wiedemann K . Metyrapone as additive treatment in major depression: A double‐blind and placebo‐controlled trial. Arch Gen Psychiatry 61: 1235‐1244, 2004.
 189. Jakovljevic M , Pivac N , Mihaljevic‐Peles A , Mustapic M , Relja M , Ljubicic D , Marcinko D , Muck‐Seler D . The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: A double blind study. Prog Neuropsychopharmacol Biol Psychiatry 31: 399‐402, 2007.
 190. Janicak PG , Pandey GN , Sharma R , Boshes R , Bresnahan D , Davis JM . Pretreatment dexamethasone suppression test as a predictor of response to phenelzine. J Clin Psychiatry 48: 480‐482, 1987.
 191. Jansen LM , Gispen‐de Wied CC , Kahn RS . Selective impairments in the stress response in schizophrenic patients. Psychopharmacology 149: 319‐325, 2000.
 192. Jansen LM , Gispen‐de Wied CC , Wiegant M , Westenberg HG , Lahuis BE , vanEngeland H . Autonomic and neuroendocrine responses to a psychosocial stressor in adults with autistic spectrum disorder. J Autism Dev Disord 36: 891‐899, 2006.
 193. Jarrett DB , Pollock B , Miewald JM , Kupfer DJ . Acute effect of intravenous clomipramine upon sleep‐related hormone secretion in depressed outpatients and healthy control subjects. Biol Psychiatry 29: 3‐14, 1991.
 194. Jensen JB , Realmuto GM , Garfinkel BD . The dexamethasone suppression test in infantile autism. J Am Acad Child Psychiatry 24: 263‐265, 1985.
 195. Jesova D , Makatsori A , Duncko R , Moncek F , Jakubek M . High trait anxiety in healthy subjects is associated with low neuroendocrine activity during psychosocial stress. Prog Neuropsychopharmacol Biol Psychiatry 28: 1331‐1336, 2004.
 196. Jezova D , Vigas M , Hlavacova N , Kukumberg P . Attenuated neuroendocrine response to hypoglycemic stress in patients with panic disorder. Neuroendocrinology 92: 112‐119, 2010.
 197. Joseph‐Vanderpool JR , Rosenthal NE , Chrousos GP , Wehr TA , Skwerer R , Kasper S , Gold PW . Abnormal pituitary‐adrenal responses to corticotropin‐releasing hormone in patients with seasonal affective disorder: Clinical and pathophysiological implications. J Clin Endocrinol Metab 72: 1382‐1387, 1991.
 198. Jovanovic T , Phifer JE , Sicking K , Weiss T , Norrholm SD , Bradley B , Ressler KJ . Cortisol suppression by dexamethasone reduces exaggerated fear responses in posttraumatic stress disorder. Psychoneuroendocrinology 36: 1540‐1552, 2011.
 199. Kabbaj M , Piazza PV , Simon H , Le Moal M , Maccari S . Opposite effects on hippocampal corticosteroid receptors induced by stimulation of beta and alpha 1 noradrenergic receptors. Neuroscience 66: 539‐545, 1995.
 200. Kahn RS , Siever L , Davidson M , Greenwald C , Moore C . Haloperidol and clozapine treatment and their effect on M‐chlorophenylpiperazine‐mediated responses in schizophrenia: Implications for the mechanism of action of clozapine. Psychopharmacology 12(1 Suppl): S90‐94, 1993.
 201. Kalsbeek A , van der Spek R , Lei J , Endert E , Buijs RM , Fliers E . Circadian rhythms in the hypothalamo‐pituitary‐adrenal (HPA) axis. Mol Cell Endocrinol 349: 20‐29, 2012.
 202. Kaneko M , Yokoyama F , Hoshino Y , Takahagi K , Murata S , Watanabe M , Kumashiro H . Hypothalamic‐pituitary‐adrenal axis function in chronic schizophrenia: Association with clinical features. Neuropsychobiology 25: 1‐7, 1992.
 203. Kathol RG , Anton R , Noyes R , Gehris T . Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder. Biol Psychiatry 25: 873‐878, 1989.
 204. Kathol RG , Gehris TL , Carroll BT , Samuelson SD , Pitts AF , Meller WH , Carter JL . Blunted ACTH response to hypoglycemic stress in depressed patients but not in patients with schizophrenia. J Psychiatr Res 26: 103‐116, 1992.
 205. Kauffman RP , Castracane VD , White DL , Baldock SD , Owens R . Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non‐depressed euglycemic women of reproductive age. Gynecol Endocrinol 21: 129‐137, 2005.
 206. Keitner GI , Fruzzetti AE , Miller IW , Norman WH , Brown WA . The effect of anticonvulsants on the dexamethasone suppression test. Can J Psychiatry 34: 441‐443, 1989.
 207. Keller J , Flores B , Gomez RG , Solvason HB , Kenna H , Williams GH , Schatzberg AF . Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry 60: 275‐281, 2006.
 208. Kellner M , Schick M , Yassouridis A , Struttmann T , Wiedemann K , Alm B . Metyrapone tests in patients with panic disorder. Biol Psychiatry 56: 898‐900, 2004.
 209. Kellner M , Wiedemann K , Yassouridis A , Muhtz C . Non‐response of cortisol during stressful exposure therapy in patients with obsessive‐compulsive disorder–preliminary results. Psychiatry Res 199: 111‐114, 2012.
 210. Kenna HA , Poon AW , de los Angeles CP , Koran LM . Psychiatric complications of treatment with corticosteroids: Review with case report. Psychiatry Clin Neurosci 65: 549‐560, 2011.
 211. Kessler RC . The costs of depression. Psychiatr Clin North Am 35: 1‐14, 2012.
 212. Khanna S , John JP , Reddy LP . Neuroendocrine and behavioral responses to mCPP in Obsessive‐Compulsive Disorder. Psychoneuroendocrinology 26: 209‐223, 2001.
 213. Kidd SA , Corbett BA , Granger DA , Boyce WT , Anders TF , Tager IB . Daytime secretion of salivary cortisol and alpha‐amylase in preschool‐aged children with autism and typically developing children. J Autism Dev Disord 42: 2648‐2658, 2012.
 214. Kier A , Han J , Jacobson L . Chronic treatment with the monoamine oxidase inhibitor phenelzine increases hypothalamic‐pituitary‐adrenocortical activity in male C57BL/6 mice: Relevance to atypical depression. Endocrinology 146: 1338‐1347, 2005.
 215. Kiive E , Maaroos J , Shlik J , Tõru I , Harro J . Growth hormone, cortisol and prolactin responses to physical exercise: Higher prolactin response in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 28: 1007‐1013, 2004.
 216. Kinney DK , Munir KM , Crowley DJ , Miller AM . Prenatal stress and risk for autism. Neurosci Biobehav Rev 32: 1519‐1532, 2008.
 217. Klein E , Zinder O , Colin V , Zilberman I , Levy N , Greenberg A , Lenox RH . Clinical similarity and biological diversity in the response to alprazolam in patients with panic disorder and generalized anxiety disorder. Acta Psychiatr Scand 92: 399‐408, 1995.
 218. Kluge M , Schüssler P , Künzel HE , Dresler M , Yassouridis A , Steiger A . Increased nocturnal secretion of ACTH and cortisol in obsessive compulsive disorder. J Psychiatr Res 41: 928‐933, 2007.
 219. Korbonits M , Trainer PJ , Edwards R , Besser GM , Grossman AB . Benzodiazepines attenuate the pituitary‐adrenal responses to corticotrophin‐releasing hormone in healthy volunteers, but not in patients with Cushing's syndrome. Clin Endocrinol 43: 29‐35, 1995.
 220. Koulu M , Scheinin M , Kaarttinen A , Kallio J , Pyykkö K , Vuorinen J , Zimmer RH . Inhibition of monoamine oxidase by moclobemide: Effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 27: 243‐255, 1989.
 221. Krämer M , Seefeldt WL , Heinrichs N , Tuschen‐Caffier B , Schmitz J , Wolf OT , Blechert J . Subjective, autonomic, and endocrine reactivity during social stress in children with social phobia. J Abnorm Child Psychol 40: 95‐104, 2012.
 222. Kunugi H , Ida I , Owashi T , Kimura M , Inoue Y , Nakagawa S , Yabana T , Urushibara T , Kanai R , Aihara M , Yuuki N , Otsubo T , Oshima A , Kudo K , Inoue T , Kitaichi Y , Shirakawa O , Isogawa K , Nagayama H , Kamijima K , Nanko S , Kanba S , Higuchi T , Mikuni M . Assessment of the dexamethasone/CRH test as a state‐dependent marker for hypothalamic‐pituitary‐adrenal (HPA) axis abnormalities in major depressive episode: A Multicenter Study. Neuropsychopharmacology 31: 212‐220, 2006.
 223. Künzel HE , Binder EB , Nickel T , Ising M , Fuchs B , Majer M , Pfennig A , Ernst G , Kern N , Schmid DA , Uhr M , Holsboer F , Modell S . Pharmacological and nonpharmacological factors influencing hypothalamic‐pituitary‐adrenocortical axis reactivity in acutely depressed psychiatric in‐patients, measured by the Dex‐CRH test. Neuropsychopharmacology 28: 2169‐2178, 2003.
 224. Künzel HE , Zobel AW , Nickel T , Ackl N , Uhr M , Sonntag A , Ising M , Holsboer F . Treatment of depression with the CRH‐1‐receptor antagonist R121919: Endocrine changes and side effects. J Psychiatr Res 37: 525‐533, 2003.
 225. Künzel HE , Ackl N , Hatzinger M , Held K , Holsboer‐Trachsler E , Ising M , Kaschka W , Kasper S , Konstantinidis A , Sonntag A , Uhr M , Yassouridis A , Holsboer F , Steiger A . Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol–a double‐blind multicenter trial. J Psychiatr Res 43: 702‐710, 2009.
 226. Kurland HD . Physiologic treatment of depressive reactions: A pilot study. Am J Psychiatry 122: 457‐458, 1965.
 227. Kvetnanský R , Pacak K , Fukuhara K , Viskupic E , Hiremagalur B , Nankova B , Goldstein DS , Sabban EL , Kopin IJ . Sympathoadrenal system in stress. Interaction with the hypothalamic‐pituitary‐adrenocortical system. Ann N Y Acad Sci 771: 131‐158, 1995.
 228. Laakmann G , Wittmann M , Gugath M , Mueller OA , Treusch J , Wahlster U , Stalla GK . Effects of psychotropic drugs (desimipramine, chlorimipramine, sulpiride and diazepam) on the human HPA axis. Psychopharmacology 84: 66‐70, 1984.
 229. Laakmann G , Hennig J , Baghai T , Schüle C . Influence of mirtazapine on salivary cortisol in depressed patients. Neuropsychobiology 47: 31‐36, 2003.
 230. Lai M , McCormick JA , Chapman KE , Kelly PA , Seckl JR , Yau JL . Differential regulation of corticosteroid receptors by monoamine neurotransmitters and antidepressant drugs in primary hippocampal culture. Neuroscience 118: 975‐984, 2003.
 231. Lam KS , Aman MG , Arnold LE . Neurochemical correlates of autistic disorder: A review of the literature. Res Dev Disabil 27: 254‐289, 2006.
 232. Lanni KE , Schupp CW , Simon D , Corbett BA . Verbal ability, social stress, and anxiety in children with autistic disorder. Autism 16: 123‐138, 2012.
 233. Laplante P , Diorio J , Meaney MJ . Serotonin regulates hippocampal glucocorticoid receptor expression via a 5‐HT7 receptor. Brain Res Dev Brain Res 139: 199‐203, 2002.
 234. Laurin C , Moullec G , Bacon SL , Lavoie KL . Impact of anxiety and depression on chronic obstructive pulmonary disease exacerbation risk. Am J Respir Crit Care Med 185: 918‐923, 2012.
 235. Lenze EJ , Mantella RC , Shi P , Goate AM , Nowotny P , Butters MA , Andreescu C , Thompson PA , Rollman BL . Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: A placebo‐controlled evaluation of escitalopram. Am J Geriatr Psychiatry 19: 482‐490, 2011.
 236. Lerer B , Gelfin Y , Gorfine M , Allolio B , Lesch KP , Newman ME . 5‐HT1A receptor function in normal subjects on clinical doses of fluoxetine: Blunted temperature and hormone responses to ipsapirone challenge. Neuropsychopharmacology 20: 628‐639, 1999.
 237. Levin AP , Saoud JB , Strauman T , Gorman JM , Flyer AJ , Crawford R , Liebowitz MR . Responses of “generalized” and “discrete” social phobics during public speaking. J Anxiety Disord 7: 207‐221, 1993.
 238. Levin N , Shinsako J , Dallman MF . Corticosterone acts on the brain to inhibit adrenalectomy‐induced adrenocorticotropin secretion. Endocrinology 122: 694‐701, 1988.
 239. Levitan RD , Kaplan AS , Brown GM , Joffe RT , Levitt AJ , Vaccarino FJ , Kennedy SH . Low plasma cortisol in bulimia nervosa patients with reversed neurovegetative symptoms of depression. Biol Psychiatry 41: 366‐368, 1997.
 240. Levitan RD , Vaccarino FJ , Brown GM , Kennedy SH . Low‐dose dexamethasone challenge in women with atypical major depression: Pilot study. J Psychiatry Neurosci 27: 47‐51, 2002.
 241. Leyton M , Bélanger C , Martial J , Beaulieu S , Corin E , Pecknold J , Kin NM , Meaney M , Thavundayil J , Larue S , Nair NP . Cardiovascular, neuroendocrine, and monoaminergic responses to psychological stressors: Possible differences between remitted panic disorder patients and healthy controls. Biol Psychiatry 40: 353‐360, 1996.
 242. Liberzon I , Abelson JL , Flagel SB , Raz J , Young EA . Neuroendocrine and psychophysiologic responses in PTSD: A symptom provocation study. Neuropsychopharmacology 21: 40‐50, 1999.
 243. Licinio J , O'Kirwan F , Irizarry K , Merriman B , Thakur S , Jepson R , Lake S , Tantisira KG , Weiss ST , Wong ML . Association of a corticotropin‐releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican‐Americans. Mol Psychiatry 9: 1075‐1082, 2004.
 244. Lindenmayer JP , Adityanjee , Vital‐Herne M , Bark N , Grochowski S , Moynihan N . Heterogeneity of serotonergic response in treatment‐refractory schizophrenia patients. Biol Psychiatry 42: 6‐12, 1997.
 245. Linkowski P , Kerkhofs M , Van Onderbergen A , Hubain P , Copinschi G , L'Hermite‐Balériaux M , Leclercq R , Brasseur M , Mendlewicz J , Van Cauter E . The 24‐hour profiles of cortisol, prolactin, and growth hormone secretion in mania. Arch Gen Psychiatry 51: 616‐624, 1994.
 246. Linkowski P . Neuroendocrine profiles in mood disorders. Int J Neuropsychopharmacol 6: 191‐197, 2003.
 247. Liu JH , Muse K , Contreras P , Gibbs D , Vale W , Rivier J , Yen SS . Augmentation of ACTH‐releasing activity of synthetic corticotropin releasing factor (CRF) by vasopressin in women. J Clin Endocrinol Metab 57: 1087‐1089, 1983.
 248. Liu Z , Zhu F , Wang G , Xiao Z , Tang J , Liu W , Wang H , Liu H , Wang X , Wu Y , Cao Z , Li W . Association study of corticotropin‐releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett 414: 155‐158, 2007.
 249. Loosen PT. In: Blevins LS . Cushing's Syndrome. Boston: Kluwer Academic, 2002, p. 45‐64.
 250. Lopez AL , Kathol RG , Noyes Jr R . Reduction in urinary free cortisol during benzodiazepine treatment of panic disorder. Psychoneuroendocrinology 15: 23‐28, 1990.
 251. Lopez JF , Chalmers DT , Little KY , Watson SJ . A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: Implications for the neurobiology of depression. Biol Psychiatry 43: 547‐573, 1998.
 252. Lowry CA . Functional subsets of serotonergic neurones: Implications for control of the hypothalamic‐pituitary‐adrenal axis. J Neuroendocrinol 14: 911‐923, 2002.
 253. Lucey JV , Barry S , Webb MG , Dinan TG . The desipramine‐induced growth hormone response and the dexamethasone suppression test in obsessive‐compulsive disorder. Acta Psychiatr Scand 86: 367‐370, 1992.
 254. Lucey JV , O'Keane V , Butcher G , Clare AW , Dinan TG . Cortisol and prolactin responses to d‐fenfluramine in non‐depressed patients with obsessive‐compulsive disorder: A comparison with depressed and healthy controls. Br J Psychiatry 161: 517‐521, 1992.
 255. Maccari S , Le Moal M , Angelucci L , Mormede P . Influence of 6‐OHDA lesion of central noradrenergic systems on corticosteroid receptors and neuroendocrine responses to stress. Brain Res 533: 60‐65, 1990.
 256. Maccari S , Piazza PV , Rouge‐Pont F , Angelucci L , Simon H , Le Moal M . Noradrenergic regulation of type‐I and type‐II corticosteroid receptors in amygdala and hypothalamus. Brain Res 587: 313‐318, 1992.
 257. Maguire KP , Schweitzer I , Biddle N , Bridge S , Tiller JW . The dexamethasone suppression test: Importance of dexamethasone concentrations. Biol Psychiatry 22: 957‐967, 1987.
 258. Makatsori A , Duncko R , Moncek F , Loder I , Katina S , Jezova D . Modulation of neuroendocrine response and non‐verbal behavior during psychosocial stress in healthy volunteers by the glutamate release‐inhibiting drug lamotrigine. Neuroendocrinology 79: 34‐42, 2004.
 259. Makino S , Gold PW , Schulkin J . Corticosterone effects on corticotropin‐releasing hormone mRNA in the central nucleus of the amygdala and the parvocellular region of the paraventricular nucleus of the hypothalamus. Brain Res 640: 105‐112, 1994.
 260. Manji HK , Hsiao JK , Risby ED , Oliver J , Rudorfer MV , Potter WZ . The mechanisms of action of lithium. I. Effects on serotoninergic and noradrenergic systems in normal subjects. Arch Gen Psychiatry 48: 505‐512, 1991.
 261. Mann K , Rossbach W , Müller MJ , Müller‐Siecheneder F , Pott T , Linde I , Dittmann RW , Hiemke C . Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 31: 256‐264, 2006.
 262. Markianos M , Hatzimanolis J , Lykouras L . Switch from neuroleptics to clozapine does not influence pituitary‐gonadal axis hormone levels in male schizophrenic patients. Eur Neuropsychopharmacology 9: 533‐536, 1999.
 263. Marshall RD , Blanco C , Printz D , Liebowitz MR , Klein DF , Coplan J . A pilot study of noradrenergic and HPA axis functioning in PTSD vs. panic disorder. Psychiatry Res 110: 219‐230, 2002.
 264. Martel FL , Hayward C , Lyons DM , Sanborn K , Varady S , Schatzberg AF . Salivary cortisol levels in socially phobic adolescent girls. Depress Anxiety 10: 25‐27, 1999.
 265. Martin EI , Ressler KJ , Binder E , Nemeroff CB . The neurobiology of anxiety disorders: Brain imaging, genetics, and psychoneuroendocrinology. Psychiatr Clin North Am 32: 549‐575, 2009.
 266. Mason BL , Thomas SA , Lightman SL , Pariante CM . Desipramine treatment has minimal effects on the brain accumulation of glucocorticoids in P‐gp‐deficient and wild‐type mice. Psychoneuroendocrinology 36: 1351‐1360, 2011.
 267. Mason JW , Giller EL , Kosten TR , Ostroff RB , Podd L . Urinary free‐cortisol levels in posttraumatic stress disorder patients. J Nerv Ment Dis 174: 145‐149, 1986.
 268. Meador‐Woodruff JH , Greden JF . Effects of psychotropic medications on hypothalamic‐pituitary‐adrenal regulation. Endocrinol Metab Clinics N Am 17: 225‐234, 1988.
 269. Medina A , Seasholtz AF , Sharma V , Burke S , Bunney W , Myers RM , Schatzberg A , Akil H , Watson SJ . Glucocorticoid and mineralocorticoid receptor expression in the human hippocampus in major depressive disorder. J Psychiatr Res 47: 307‐314, 2013.
 270. Meier A , Neumann A‐C , Jordan W , Heuther G , Rodenbeck A , Ruther E , Cohrs S . Ziprasidone decreases cortisol excretion in healthy subjects. Br J Clin Pharmacol 60: 330‐336, 2005.
 271. Meijer OC , de Lange EC , Breimer DD , de Boer AG , Workel JO , de Kloet ER . Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P‐glycoprotein knockout mice. Endocrinology 139: 1789‐1793, 1998.
 272. Meltzer H , Bastani B , Jayathilake K , Maes M . Fluoxetine, but not tricyclic antidepressants, potentiates the 5‐hydroxytryptophan‐mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. Neuropsychopharmacology 17: 1‐11, 1997.
 273. Meltzer HY , Lowy M , Robertson A , Goodnick P , Perline R . Effect of 5‐hydroxytryptophan on serum cortisol levels in major affective disorders. III. Effect of antidepressants and lithium carbonate. Arch Gen Psychiatry 41: 391‐397, 1984.
 274. Michelson D , Galliven E , Hill L , Demitrack M , Chrousos G , Gold P . Chronic imipramine is associated with diminished hypothalamic‐pituitary‐adrenal axis responsivity in healthy humans. J Clin Endocrinol Metab 82: 2601‐2606, 1997.
 275. Millet B , Touitou Y , Poirier MF , Bourdel MC , Hantouche E , Bogdan A , Olié JP . Plasma melatonin and cortisol in patients with obsessive‐compulsive disorder: Relationship with axillary temperature, physical activity, and clinical symptoms. Biol Psychiatry 44: 874‐881, 1998.
 276. Monteleone P . Effects of trazodone on plasma cortisol in normal subjects. A study with drug plasma levels. Neuropsychopharmacology 5: 61‐64, 1991.
 277. Monteleone P , Catapano F , Tortorella A , DiMartino S , Maj M . Plasma melatonin and cortisol circadian patterns in patients with obsessive‐compulsive disorder before and after fluoxetine treatment. Psychoneuroendocrinology 20: 763‐770, 1995.
 278. Muck‐Seler D , Pivac N , Sagud M , Jakovljević M , Mihaljević‐Peles A . The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. Prog Neuropsychopharmacol Biol Psychiatry 26: 1235‐1243, 2002.
 279. Muglia LJ , Jacobson L , Weninger SC , Luedke CE , Bae DS , Jeong K‐H , Majzoub JA . Impaired diurnal adrenal rhythmicity restored by constant infusion of corticotropin‐releasing hormone in CRH‐deficient mice. J Clin Invest 99: 2923‐2929, 1997.
 280. Murburg MM , Paly D , Wilkinson CW , Veith RC , Malas KL , Dorsa DM . Haloperidol increases plasma beta endorphin‐like immunoreactivity and cortisol in normal human males. Life Sci 39: 373‐381, 1986.
 281. Murrough JW , Iacoviello B , Neumeister A , Charney DS , Iosifescu DV . Cognitive dysfunction in depression: Neurocircuitry and new therapeutic strategies. Neurobiol Learn Mem 96: 553‐563, 2011.
 282. Nathan RS , Sachar EJ , Asnis GM , Halbreich U , Halpern FS . Relative insulin insensitivity and cortisol secretion in depressed patients. Psychiatry Res 4: 291‐300, 1981.
 283. Nelson EB . Psychotic depression–beyond the antidepressant/antipsychotic combination. Curr Psychiatry Rep 14: 619‐623, 2012.
 284. Nelson JC , Davis JM . DST studies in psychotic depression: A meta‐analysis. Am J Psychiatry 154: 1497‐1503, 1997.
 285. Nemeroff CB , Krishnan KR , Reed D , Leder R , Beam C , Dunnick NR . Adrenal gland enlargement in major depression. A computed tomographic study. Arch Gen Psychiatry 49: 384‐387, 1992.
 286. Nemeroff CB , Owens MJ . Pharmacologic differences among the SSRIs: Focus on monoamine transporters and the HPA axis. CNS Spectr 9 (Suppl 4): 23‐31, 2004.
 287. Nesse RM , Cameron OG , Curtis GC , McCann DS , Huber‐Smith MJ . Adrenergic function in patients with panic anxiety. Arch Gen Psychiatry 41: 771‐776, 1984.
 288. Nestler EJ , Barrot M , Dileone RJ , Eisch AJ , Gold SJ , Monteggia LM . Neurobiology of Depression. Neuron 34: 13‐25, 2002.
 289. Nickel T , Sonntag A , Schill J , Zobel AW , Ackl N , Brunnauer A , Murck H , Ising M , Yassouridis A , Steiger A , Zihl J , Holsboer F . Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol 23: 55‐68, 2003.
 290. Nikisch G , Mathé AA , Czernik A , Thiele J , Bohner J , Eap CB , Agren H , Baumann P . Long‐term citalopram administration reduces responsiveness of HPA axis in patients with major depression: Relationship with S‐citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology 181: 751‐760, 2005.
 291. Nikisch G , Mathé AA . CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy. Eur Psychiatry 23: 356‐359, 2008.
 292. Nir I , Meir D , Zilber N , Knobler H , Hadjez J , Lerner Y . Brief report: Circadian melatonin, thyroid‐stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord 25: 641‐654, 1995.
 293. O'Donnell JM , Shelton RC . Drug therapy of depression and anxiety disorders. In: Brunton LL , Blumenthal DK , Murri N , Hilal‐Dandan R , Knollmann BC , editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics (12th ed). McGraw‐Hill Companies, Inc, 2011.
 294. O'Keane V , McLoughlin D , Dinan TG . D‐fenfluramine‐induced prolactin and cortisol release in major depression: Response to treatment. J Affect Disord 26: 143‐150, 1992.
 295. O'Toole SM , Sekula LK , Rubin RT . Pituitary‐adrenal cortical axis measures as predictors of sustained remission in major depression. Biol Psychiatry 42: 85‐89, 1997.
 296. Olff M , de Vries GJ , Güzelcan Y , Assies J , Gersons BP . Changes in cortisol and DHEA plasma levels after psychotherapy for PTSD. Psychoneuroendocrinology 32: 619‐626, 2007.
 297. Otte C , Muhtz C , Daneshkhah S , Yassouridis A , Kiefer F , Wiedemann K , Kellner M . Mineralocorticoid receptor function in posttraumatic stress disorder after pretreatment with metyrapone. Biol Psychiatry 60: 784‐787, 2006.
 298. Owen RR , Gutierrez‐Esteinou R , Hsiao J , Hadd K , Benkelfat C , Lawlor BA , Murphy DL , Pickar D . Effects of clozapine and fluphenazine treatment on responses to m‐chlorophenylpiperazine infusions in schizophrenia. Arch Gen Psychiatry 50: 636‐644, 1993.
 299. Owens MJ , Bissette G , Nemeroff CB . Acute effects of alprazolam and adinazolam on the concentrations of corticotropin‐releasing factor in the rat brain. Synapse 4: 196‐202, 1989.
 300. Pace TW , Miller AH . Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci 1179: 86‐105, 2009.
 301. Pace TWW , Spencer RL . Disruption of mineralocorticoid receptor function increases corticosterone responding to a mild, but not moderate, psychological stressor. Am J Physiol 288: E1082‐1088, 2005.
 302. Pan A , Sun Q , Okereke OI , Rexrode KM , Hu FB . Depression and risk of stroke morbidity and mortality: A meta‐analysis and systematic review. JAMA 306: 1241‐1249, 2011.
 303. Papadopoulos V , Miller WL . Role of mitochondria in steroidogenesis. Best Pract Res Clin Endocrinol Metab 26: 771‐790, 2012.
 304. Papakostas G , Chuzi SE , Sousa JL , Fava M . 5HT1A‐mediated stimulation of cortisol release in major depression: Use of non‐invasive cortisol measurements to predict clinical response. Eur Arch Psychiatry Clin Neurosci 260: 175‐180, 2010.
 305. Pariante CM , Miller AH . Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biol Psychiatry 49: 391‐404, 2001.
 306. Pariante CM , Thomas SA , Lovestone S , Makoff A , Kerwin RW . Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology 29: 423‐447, 2004.
 307. Parker G , Roy K , Mitchell P , Wilhelm K , Malhi G , Hadzi‐Pavlovic D . Atypical depression: A reappraisal. Am J Psychiatry 159: 1470‐1479, 2002.
 308. Paslakis G , Heuser I , Schweiger U , Deuschle M . A single DEX/CRH test in male drug‐free depressed patients is associated with the clinical response to treatment with fluoxetine. J Psychiatr Res 44: 1154‐1157, 2010.
 309. Penninx BW , Beekman AT , Bandinelli S , Corsi AM , Bremmer M , Hoogendijk WJ , Guralnik JM , Ferrucci L . Late‐life depressive symptoms are associated with both hyperactivity and hypoactivity of the hypothalamo‐pituitary‐adrenal axis. Am J Geriatr Psychiatry 15: 522‐529, 2007.
 310. Perini GI , Devinsky O , Hauser P , Gallucci WT , Theodore HW , Chrousos GP , Gold PW , Kling MA . Effects of carbamazepine on pituitary‐adrenal function in healthy volunteers. J Clin Endocrinol Metab 74: 406‐412, 1992.
 311. Perlman WR , Webster MJ , Kleinman JE , Weickert CS . Reduced glucocorticoid and estrogen receptor alpha messenger ribonucleic acid levels in the amygdala of patients with major mental illness. Biol Psychiatry 56: 844‐852, 2004.
 312. Petraglia F , Bakalakis S , Facchinetti F , Volpe A , Muller EE , Genazzini AR . Effects of sodium valproate and diazepam on beta‐endorphin, beta‐lipotropin and cortisol secretion induced by hypoglycemic stress in humans. Neuroendocrinology 44: 320‐325, 1986.
 313. Petrowski K , Herold U , Joraschky P , Wittchen HU , Kirschbaum C . A striking pattern of cortisol non‐responsiveness to psychosocial stress in patients with panic disorder with concurrent normal cortisol awakening responses. Psychoneuroendocrinology 35: 414‐421, 2010.
 314. Pietrzak RH , Goldstein RB , Southwick SM , Grant BF . Medical comorbidity of full and partial posttraumatic stress disorder in US adults: Results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med 73: 697‐707, 2011.
 315. Player MS , Peterson LE . Anxiety disorders, hypertension, and cardiovascular risk: A review. Int J Psychiatry Med 41: 365‐377, 2011.
 316. Plotsky PM , Thrivikraman KV , Meaney MJ . In: Vale WW , editor. CIBA Foundation Symposium. Chichester: John Wiley and Sons, 1993, p. 59‐75.
 317. Pomara N , Willoughby LM , Sidtis JJ , Cooper TB , Greenblatt DJ . Cortisol response to diazepam: Its relationship to age, dose, duration of treatment, and presence of generalized anxiety disorder. Psychopharmacology 178: 1‐8, 2005.
 318. Putignano P , Kaltsas GA , Satta MA , Grossman AB . The effects of anti‐convulsant drugs on adrenal function. Horm Metab Res 30: 389‐397, 1998.
 319. Radley JJ , Kabbaj M , Jacobson L , Heydendael W , Yehuda R , Herman JP . Stress risk factors and stress‐related pathology: Neuroplasticity, epigenetics and endophenotypes. Stress 14: 481‐497, 2011.
 320. Rakofsky JJ , Holtzheimer PE , Nemeroff CB . Emerging targets for antidepressant therapies. Curr Opin Chem Biol 13: 291‐302, 2009.
 321. Rao U , Ott GE , Lin KM , Gertsik L , Poland RE . Effect of bupropion on nocturnal urinary free cortisol and its association with antidepressant response. J Psychiatr Res 39: 183‐190, 2005.
 322. Raskin DE . Steroid‐induced panic disorder. Am J Psychiatry 141: 1647, 1984.
 323. Ravindran LN , Stein MB . The pharmacologic treatment of anxiety disorders: A review of progress. J Clin Psychiatry 71: 839‐854, 2010.
 324. Ribeiro SC , Tandon R , Grunhaus L , Greden JF . The DST as a predictor of outcome in depression: A meta‐analysis. Am J Psychiatry 150: 1618‐1629, 1993.
 325. Richdale AL , Prior MR . Urinary cortisol circadian rhythm in a group of high‐functioning children with autism. J Autism Dev Disord 22: 433‐447, 1992.
 326. Ritsner M , Gibel A , Maayan R , Ratner Y , Ram E , Biadsy H , Modai I , Weizman A . Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. Neuropsychopharmacology 30: 1913‐1922, 2005.
 327. Robertson DAF , Beattie JE , Reid IC , Balfour DJK . Regulation of corticosteroid receptors in the rat brain: The role of serotonin and stress. Eur J Neuroscience 21: 1511‐1526, 2005.
 328. Roelofs K , van Peer J , Berretty E , de Jong P , Spinhoven P , Elzinga BM . Hypothalamus‐pituitary‐adrenal axis hyperresponsiveness is associated with increased social avoidance behavior in social phobia. Biol Psychiatry 65: 336‐343, 2009.
 329. Rohrer T , von Richthofen V , Schulz C , Beyer J , Lehnert H . The stress‐, but not corticotropin‐releasing hormone‐induced activation of the pituitary‐adrenal axis in man is blocked by alprazolam. Horm Metab Res 26: 200‐206, 1994.
 330. Romer B , Lewicka S , Kopf D , Lederbogen F , Hamann B , Gilles M , Schilling C , Onken V , Frankhauser P , Deuschle M . Cortisol metabolism in depressed patients and healthy controls. Neuroendocrinology 90: 301‐306, 2009.
 331. Rosenbaum AH , Maruta T , Schatzberg AF , Orsulak P , Jiang NS , Cole JO , Schildkraut JJ . Toward a biochemical classification of depressive disorders, VII: Urinary free cortisol and urinary MHPG in depressions. Am J Psychiatry 140: 314‐318, 1983.
 332. Rosenstock J , Banarer S , Fonseca VA , Inzucchi SE , Sun W , Yao W , Hollis G , Flores R , Levy R , Williams WW , Seckl JR , Huber R , INCB13739‐202PrincipalInvestigators. The 11‐beta‐hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33: 1516‐1522, 2010.
 333. Rota E , Broda R , Cangemi L , Migliaretti G , Paccotti P , Rosso C , Torre E , Zeppegno P , Portaleone P . Neuroendocrine (HPA axis) and clinical correlates during fluvoxamine and amitriptyline treatment. Psychiatry Res 133: 281‐284, 2005.
 334. Roy‐Byrne PP , Cowley DS , Hommer D , Ritchie J , Greenblatt D , Nemeroff C . Neuroendocrine effects of diazepam in panic and generalized anxiety disorders. Biol Psychiatry 30: 73‐80, 1991.
 335. Roy A , Pickar D , Doran A , Wolkowitz O , Gallucci W , Chrousos G , Gold P . The corticotropin‐releasing hormone stimulation test in chronic schizophrenia. Am J Psychiatry 143: 1393‐1397, 1986.
 336. Rubin RT , Poland RE , Lesser IM , Winston RA , Blodgett AL . Neuroendocrine aspects of primary endogenous depression. I. Cortisol secretory dynamics in patients and matched controls. Arch Gen Psychiatry 44: 328‐336, 1987.
 337. Rubin RT , Phillips JJ , Sadow TF , McCracken JT . Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment. Arch Gen Psychiatry 52: 213‐218, 1995.
 338. Rush AJ , Giles DE , Schlesser MA , Orsulak PJ , Parker Jr CR , Weissenburger JE , Crowley GT , Khatami M , Vasavada N . The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry 57: 470‐484, 1996.
 339. Rush AJ , Kraemer HC , Sackeim HA , Fava M , Trivedi MH , Frank E , Ninan PT , Thase ME , Gelenberg AJ , Kupfer DJ , Regier DA , Rosenbaum JF , Ray O , Schatzberg AF , ACNP Task Force. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 31: 1841‐1853, 2006.
 340. Ryan MC , Sharifi N , Condren R , Thakore JH . Evidence of basal pituitary‐adrenal overactivity in first episode, drug naïve patients with schizophrenia. Psychoneuroendocrinology 29: 1065‐1070, 2004.
 341. Rybakowski JK , Suwalska A , Chlopocka‐Woźniak M . Potentiation of antidepressants with lithium or carbamazepine in treatment‐resistant depression. Neuropsychobiology 40: 134‐139, 1999.
 342. Sachdeo RC , Wasserstein A , Mesenbrink PJ , D'Souza J . Effects of oxcarbazepine on sodium concentration and water handling. Ann Neurol 51: 613‐620, 2002.
 343. Sagud M , Pivac N , Mück‐Seler D , Jakovljević M , Mihaljević‐Peles A , Korsić M . Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Neuropsychobiology 45: 139‐143, 2002.
 344. Sallee FR , Koran LM , Pallanti S , Carson SW , Sethuraman G . Intravenous clomipramine challenge in obsessive‐compulsive disorder: Predicting response to oral therapy at eight weeks. Biol Psychiatry 44: 220‐227, 1998.
 345. Salvadore G , Quiroz JA , Machado‐Vieira R , Henter D , Manji HK , Zarate Jr CA . The neurobiology of the switch process in bipolar disorder: A review. J Clin Psychiatry 71: 1488‐1501, 2010.
 346. Sanders‐Bush E , Hazelwood L . 5‐Hydroxytryptamine (Serotonin) and Dopamine. In: Brunton LL , Blumenthal DK , Murri N , Hilal‐Dandan R , Knollmann BC , editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics (12th ed). McGraw‐Hill Companies, Inc, 2011.
 347. Santagostino G , Amoretti G , Frattini P , Zerbi F , Cucchi ML , Preda S , Corona GL . Catecholaminergic, neuroendocrine and anxiety responses to acute psychological stress in healthy subjects: Influence of alprazolam administration. Neuropsychobiology 34: 36‐43, 1996.
 348. Santagostino G , Cucchi ML , Frattini P , Zerbi F , Paolo ED , Preda S , Corona GL . The influence of alprazolam on the monoaminergic neurotransmitter systems in dysthymic patients. Relationship to clinical response. Pharmacopsychiatry 31: 131‐136, 1998.
 349. Sapolsky RM , Romero LM , Munck AU . How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocrine Rev 21: 55‐89, 2000.
 350. Sargent P , Williamson DJ , Pearson G , Odontiadis J , Cowen PJ . Effect of paroxetine and nefazodone on 5‐HT1A receptor sensitivity. Psychopharmacology 132: 296‐302, 1997.
 351. Sawchenko PE , Imaki T , Potter E , Kovács K , Imaki J , Vale W . The functional neuroanatomy of corticotropin‐releasing factor. Ciba Found Symp 172: 5‐21, 1993.
 352. Scharnholz B , Weber‐Hamann B , Lederbogen F , Schilling C , Gilles M , Onken V , Frankhauser P , Kopf D , Deuschle M . Antidepressant treatment with mirtazapine, but not venlafaxine, lowers cortisol concentrations in saliva: A randomised open trial. Psychiatry Res 177: 109‐113, 2010.
 353. Schatzberg AF , Rothschild AJ , Langlais PJ , Bird ED , Cole JO . A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 19: 57‐64, 1985.
 354. Schatzberg AF , Rothschild AJ . Psychotic (delusional) major depression: Should it be included as a distinct syndrome in DSM‐IV? Am J Psychiatry 149: 733‐745, 1992.
 355. Schatzberg AF , Lindley S . Glucocorticoid antagonists in neuropsychiatric disorders. Eur J Pharmacol 583: 358‐364, 2008.
 356. Scheepers FE , Gispen‐de Wied CC , Kahn RS . The effect of olanzapine treatment on m‐chlorophenylpiperazine‐induced hormone release in schizophrenia. J Clin Psychopharmacol 21: 575‐582, 2001.
 357. Schelling G , Roozendaal B , Krauseneck T , Schmoelz M , de Quervain D , Briegel J . Efficacy of hydrocortisone in preventing posttraumatic stress disorder following critical illness and major surgery. Ann N Y Acad Sci 1071: 46‐53, 2006.
 358. Schreiber W , Lauer CJ , Krumrey K , Holsboer F , Krieg JC . Dysregulation of the hypothalamic‐pituitary‐adrenocortical system in panic disorder. Neuropsychopharmacology 15: 7‐15, 1996.
 359. Schruers K , van Diest R , Nicolson N , Griez E . L‐5‐hydroxytryptophan induced increase in salivary cortisol in panic disorder patients and healthy volunteers. Psychopharmacology 161: 365‐369, 2002.
 360. Schuckit MA , Hauger R , Klein JL . Adrenocorticotropin hormone response to diazepam in healthy young men. Biol Psychiatry 31: 661‐669, 1992.
 361. Schüle C , Baghai T , Bidlingmaier M , Strasburger C , Laakmann G . Endocrinological effects of mirtazapine in healthy volunteers. Prog Neuropsychopharmacol Biol Psychiatry 26: 1253‐1261, 2002.
 362. Schüle C . Neuroendocrinological mechanisms of actions of antidepressant drugs. J Neuroendocrinol 19: 213‐226, 2007.
 363. Scott LV , Dinan TG . Urinary free cortisol excretion in chronic fatigue syndrome, major depression and in healthy volunteers. J Affect Disord 47: 49‐54, 1998.
 364. Sevy S , Brown SL , Wetzler S , Kotler M , Molcho A , Plutchik R , van Praag HM . Effects of alprazolam on increases in hormonal and anxiety levels induced by meta‐chlorophenylpiperazine. Psychiatry Res 53: 219‐229, 1994.
 365. Sharpley CF . A review of the neurobiological effects of psychotherapy for depression. Psychotherapy 47: 603‐615, 2010.
 366. Shepard JD , Barron KW , Myers DA . Corticosterone delivery to the amygdala increases corticotropin‐releasing factor mRNA in the central amygdaloid nucleus and anxiety‐like behavior. Brain Res 861: 288‐295, 2000.
 367. Shepard JD , Barron KW , Myers DA . Stereotaxic localization of corticosterone to the amygdala enhances hypothalamo‐pituitary‐adrenal responses to behavioral stress. Brain Res 963: 203‐213, 2003.
 368. Shiah IS , Yatham LN , Lam RW , Zis AP . Effects of divalproex sodium on 5‐HT1A receptor function in healthy human males: Hypothermic, hormonal, and behavioral responses to ipsapirone. Neuropsychopharmacology 17: 382‐390, 1997.
 369. Shirayama Y , Hashimoto K , Suzuki Y , Higuchi T . Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia. Schizophr Res 58: 69‐74, 2002.
 370. Shirotsuki K , Izawa S , Sugaya N , Yamada KC , Ogawa N , Ouchi Y , Nagano Y , Nomura S . Salivary cortisol and DHEA reactivity to psychosocial stress in socially anxious males. Int J Psychophysiol 72: 198‐203, 2009.
 371. Siegmund A , Köster L , Meves AM , Plag J , Stoy M , Ströhle A . Stress hormones during flooding therapy and their relationship to therapy outcome in patients with panic disorder and agoraphobia. J Psychiatr Res 45: 339‐346, 2011.
 372. Silberman EK , Post RM . Atypicality in primary depressive illness: A preliminary survey. Biol Psychiatry 17: 285‐304, 1982.
 373. Sirois F . Steroid psychosis: A review. Gen Hosp Psychiatry 25: 27‐33, 2003.
 374. Skene DJ , Bojkowski CJ , Arendt J . Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. Br J Clin Pharmacol 37: 181‐186, 1994.
 375. Smigan L , Perris C . Cortisol changes in long‐term lithium therapy. Neuropsychobiology 11: 219‐223, 1984.
 376. Smoller JW , Yamaki LH , Fagerness JA , Biederman J , Racette S , Laird NM , Kagan J , Snidman N , Faraone SV , Hirshfeld‐Becker D , Tsuang MT , Slaugenhaupt SA , Rosenbaum JF , Sklar PB . The corticotropin‐releasing hormone gene and behavioral inhibition in children at risk for panic disorder. Biol Psychiatry 57: 1485‐1492, 2005.
 377. Sonino N , Fava GA . Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs 15: 361‐373, 2001.
 378. Sonntag A , Rothe B , Guldner J , Yassouridis A , Holsboer F , Steige A . Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. Depression 4: 1‐13, 1996.
 379. Soravia LM , Heinrichs M , Aerni A , Maroni C , Schelling G , Ehlert U , Roozendaal B , de Quervain DJ . Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci USA 103: 5585‐5590, 2006.
 380. Spijker AT , Giltay EJ , van Rossum EF , Manenschijn L , Derijk RH , Haffmans J , Zitman FG , Hoencamp E . Glucocorticoid and mineralocorticoid receptor polymorphisms and clinical characteristics in bipolar disorder patients. Psychoneuroendocrinology 36: 1460‐1469, 2011.
 381. Spratt EG , Nicholas JS , Brady KT , Carpenter LA , Hatcher CR , Meekins KA , Furlanetto RW , Charles JM . Enhanced cortisol response to stress in children in autism. J Autism Dev Disord 42: 75‐81, 2012.
 382. Starkman MN , Schteingart DE . Neuropsychiatric manifestations of patients with Cushing's syndrome. Relationship to cortisol and adrenocorticotropic hormone levels. Arch Intern Med 141: 215‐219, 1981.
 383. Steckler T , Holsboer F . Corticotropin‐releasing hormone receptor subtypes and emotion. Biol Psychiatry 46: 1480‐1508, 1999.
 384. Steen NE , Methlie P , Lorentzen S , Hope S , Barrett EA , Larsson S , Mork E , Almås B , Løvås K , Agartz I , Melle I , Berg JP , Andreassen O . Increased systemic cortisol metabolism in patients with schizophrenia and bipolar disorder: A mechanism for increased stress vulnerability? J Clin Psychiatry 72: 1515‐1521, 2011.
 385. Steiger A , Benkert O , Holsboer F . Effects of long‐term treatment with the MAO‐A inhibitor moclobemide on sleep EEG and nocturnal hormone secretion in normal men. Neuropsychobiology 30: 101‐105, 1994.
 386. Stetler C , Miller GE . Depression and hypothalamic‐pituitary‐adrenal activation: A quantitative summary of four decades of research. Psychosom Med 73: 114‐126, 2011.
 387. Stewart JW , McGrath PJ , Quitkin FM . Do age of onset and course of illness predict different treatment outcome among DSM IV depressive disorders with atypical features? Neuropsychopharmacology 26: 237‐245, 2002.
 388. Stewart JW , Quitkin FM , McGrath PJ , Klein DF . Defining the boundaries of atypical depression: Evidence from the HPA axis supports course of illness distinctions. J Affective Disord 86: 161‐167, 2005.
 389. Stewart JW , McGrath PJ , Quitkin FM , Klein DF . DSM‐IV depression with atypical features: Is it valid? Neuropsychopharmacology 34: 2625‐2632, 2009.
 390. Straneva‐Meuse PA , Light KC , Allen MT , Golding M , Girdler SS . Bupropion and paroxetine differentially influence cardiovascular and neuroendocrine responses to stress in depressed patients. J Affect Disord 79: 51‐61, 2001.
 391. Ströhle A , Scheel M , Modell S , Holsboer F . Blunted ACTH response to dexamethasone suppression‐CRH stimulation in posttraumatic stress disorder. J Psychiatr Res 42: 1185‐1188, 2008.
 392. Sudheimer KD , Abelson JL , Taylor SF , Martis B , Welsh RC , Warner C , Samet M , Manduzzi A , Liberzon I . Exogenous glucocorticoids decrease subgenual cingulate activity evoked by sadness. Neuropsychopharmacology 38: 826‐845, 2013.
 393. Swann AC , Stokes PE , Casper R , Secunda SK , Bowden CL , Berman N , Katz MM , Robins E . Hypothalamic‐pituitary‐adrenocortical function in mixed and pure mania. Acta Psychiatr Scand 85: 270‐274, 1992.
 394. Swinburn CR , Wakefield JM , Newman SP , Jones PW . Evidence of prednisolone induced mood change (‘steroid euphoria’) in patients with chronic obstructive airways disease. Br J Clin Pharmacol 26: 709‐713, 1988.
 395. Tanaka K , Morinobu S , Ichimura M , Asakawa A , Inui A , Hosoda H , Kangawa K , Yamawaki S . Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n‐octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 32: 1527‐1532, 2008.
 396. Tani P , Lindberg N , Matto V , Appelberg B , Nieminen‐vonWendt T , vonWendt L , Porkka‐Heiskanen T . Higher plasma ACTH levels in adults with Asperger syndrome. J Psychosom Res 58: 533‐536, 2005.
 397. Thakore JH , Barnes C , Joyce J , Medbak S , Dinan TG . Effects of antidepressant treatment on corticotropin‐induced cortisol responses in patients with melancholic depression. Psychiatry Res 73: 27‐32, 1997.
 398. Thase M . Recognition and diagnosis of atypical depression. J Clin Psychiatry 68: 11‐16, 2007.
 399. Thase ME , Dubé S , Bowler K , Howland RH , Myers JE , Friedman E , Jarrett DB . Hypothalamic‐pituitary‐adrenocortical activity and response to cognitive behavior therapy in unmedicated, hospitalized depressed patients. Am J Psychiatry 153: 886‐891, 1996.
 400. Thase ME . Evaluating antidepressant therapies: Remission as the optimal outcome. J Clin Psychiatry 64 (Suppl 3): 18‐25, 2003.
 401. Thase ME . Achieving remission and managing relapse in depression. J Clin Psychiatry 64: 3‐7, 2003.
 402. Thase ME . Atypical depression: Useful concept, but it's time to revise the DSM‐IV criteria. Neuropsychopharmacology 34: 2633‐2641, 2009.
 403. Thomas M , Keramidas M , Monchaux E , Feige J‐J . Dual hormonal regulation of endocrine tissue mass and vasculature by adrenocorticotropin in the adrenal cortex. Endocrinology 145: 4320‐4329, 2004.
 404. Thomsen AF , Kvist TK , Andersen PK , Kessing LV . The risk of affective disorders in patients with adrenocortical insufficiency. Psychoneuroendocrinology 31: 614‐622, 2006.
 405. Thurston RC , Rewak M , Kubzansky LD . An anxious heart: Anxiety and the onset of cardiovascular diseases. Prog Cardiovasc Dis 55: 524‐537, 2013.
 406. Tordjman S , Anderson GM , McBride A , Hertzig ME , Snow ME , Hall LM , Thompson SM , Ferrari P , Cohen DJ . Plasma beta‐endorphin, adrenocorticotropin hormone, and cortisol in autism. J Child Psychol Psychiatry 38: 705‐715, 1997.
 407. Tormey WP , Dolphin C , Darragh AS . The effects of diazepam on sleep, and on the nocturnal release of growth hormone, prolactin, ACTH and cortisol. Br J Clin Pharmacol 8: 90‐92, 1979.
 408. Torpy DJ , Grice JE , Hockings GI , Walters MW , Crosbie GV , Jackson RV . Alprazolam attenuates vasopressin‐stimulated adrenocorticotropin and cortisol release: Evidence for synergy between vasopressin and corticotropin‐releasing hormone in humans. J Clin Endocrinol Metab 79: 140‐144, 1994.
 409. Torpy DJ , Grice JE , Hockings GI , Crosbie GV , Walters MM , Jackson RV . The effect of desipramine on basal and naloxone‐stimulated cortisol secretion in humans: Interaction of two drugs acting on noradrenergic control of adrenocorticotropin secretion. J Clin Endocrinol Metab 80: 802‐806, 1995.
 410. Ulrich‐Lai YM , Herman JP . Neural regulation of endocrine and autonomic stress responses. Nature Rev Neurosci 10: 397‐409, 2009.
 411. Valiengo LL , Soeiro‐de‐Souza MG , Marques AH , Moreno DH , Juruena MF , Andreazza AC , Gattaz WF , Machado‐Vieira R . Plasma cortisol in first episode drug‐naïve mania: Differential levels in euphoric versus irritable mood. J Affect Disord 138: 149‐152, 2012.
 412. van der Lely A‐J , Foeken K , van der Mast RC , Lamberts SWJ . Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol‐receptor antagonist mifepristone (RU 486). Ann Int Med 114: 143‐144, 1991.
 413. van Veen JF , van Vliet IM , Derijk RH , van Pelt J , Mertens B , Zitman FG . Elevated alpha‐amylase but not cortisol in generalized social anxiety disorder. Psychoneuroendocrinology 33: 1313‐1321, 2008.
 414. van Venrooij JA , Fluitman SB , Lijmer JG , Kavelaars A , Heijnen CJ , Westenberg HG , Kahn RS , Gispen‐de Wied CC . Impaired neuroendocrine and immune response to acute stress in medication‐naive patients with a first episode of psychosis. Schizophr Bull 38: 272‐279, 2012.
 415. van West D , Claes S , Sulon J , Deboutte D . Hypothalamic‐pituitary‐adrenal reactivity in prepubertal children with social phobia. J Affect Disord 111: 281‐290, 2008.
 416. van Zuiden M , Heijnen CJ , Maas M , Amarouchi K , Vermetten E , Geuze E , Kavelaar A . Glucocorticoid sensitivity of leukocytes predicts PTSD, depressive and fatigue symptoms after military deployment: A prospective study. Psychoneuroendocrinology 37: 1822‐1836, 2012.
 417. Vedder H , Bening‐Abu‐Shach U , Lanquillon S , Krieg JC . Regulation of glucocorticoid receptor‐mRNA in human blood cells by amitriptyline and dexamethasone. J Psychiatr Res 33: 303‐308, 1999.
 418. Veith RC , Lewis N , Langohr J , Murburg MM , Ashleigh EA , Castillo S , Peskind ER , Pascualy M , Bissette G , Nemeroff CB , Raskind MA . Effect of desipramine on cerebrospinal fluid concentrations of corticotropin‐releasing factor in human subjects. Psychiatry Res 46: 1‐8, 1993.
 419. Viau R , Arsenault‐Lapierre G , Fecteau S , Champagne N , Walker CD , Lupien S . Effect of service dogs on salivary cortisol secretion in autistic children. Psychoneuroendocrinology 35: 1187‐1193, 2010.
 420. Vidarsdottir S , Roelfsema F , Frolich M , Pijl H . Olanzapine shifts the temporal relationship between the daily acrophase of serum prolactin and cortisol concentrations rhythm in healthy men. Psychoneuroendocrinology 34: 705‐712, 2009.
 421. Vieta E , Martínez‐De‐Osaba MJ , Colom F , Martínez‐Arán A , Benabarre A , Gastó C . Enhanced corticotropin response to corticotropin‐releasing hormone as a predictor of mania in euthymic bipolar patients. Psychol Med 29: 971‐978, 1999.
 422. von Bardeleben U , Holsboer F . Human corticotropin releasing hormone: Clinical studies in patients with affective disorders, alcoholism, panic disorder and in normal controls. Prog Neuropsychopharmacol Biol Psychiatry 12 (Suppl): S165‐187, 1988.
 423. Vreeburg SA , Hoogendijk WJ , van Pelt J , Derijk RH , Verhagen JC , van Dyck R , Smit JH , Zitman FG , Penninx BW . Major depressive disorder and hypothalamic‐pituitary‐adrenal axis activity: Results from a large cohort study. Arch Gen Psychiatry 66: 617‐626, 2009.
 424. Vreeburg SA , Zitman FG , van Pelt J , Derijk RH , Verhagen JC , van Dyck R , Hoogendijk WJ , Smit JH , Penninx BW . Salivary cortisol levels in persons with and without different anxiety disorders. Psychosom Med 72: 340‐347, 2010.
 425. Vythilingam M , Gill JM , Luckenbaugh DA , Gold PW , Collin CW , Bonne O , Plumb K , Polignano E , West K , Charney D . Low early morning plasma cortisol in posttraumatic stress disorder is associated with co‐morbid depression but not with enhanced glucocorticoid feedback inhibition. Psychoneuroendocrinology 35: 442‐450, 2010.
 426. Walder DJ , Walker EF , Lewine RJ . Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol Psychiatry 48: 1121‐1132, 2000.
 427. Walker E , Mittal V , Tessner K . Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu Rev Clin Psychol 4: 189‐216, 2008.
 428. Wang Q , Verweij EW , Krugers HJ , Joels M , Swaab DF , Lucassen PJ . Distribution of the glucocorticoid receptor in the human amygdala; changes in mood disorder patients. Brain Struct Funct In press: 2013.
 429. Wang Y , Jia Y , Chen X , Ling X , Liu S , Xu G , Huang L . Hippocampal N‐acetylaspartate and morning cortisol levels in drug‐naive, first‐episode patients with major depressive disorder: Effects of treatment. J Psychopharmacol 26: 1463‐1470, 2012.
 430. Warrington TP , Bostwick JM . Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 81: 1361‐1367, 2006.
 431. Watson S , Gallagher P , Del‐Estal D , Hearn A , Ferrier IN , Young AH . Hypothalamic‐pituitary‐adrenal axis function in patients with chronic depression. Psychol Med 32: 1021‐1028, 2002.
 432. Watson S , Gallagher P , Ritchie JC , Ferrier N , Young AH . Hypothalamic‐pituitary‐adrenal axis function in patients with bipolar disorder. Br J Psychiatry 184: 496‐502, 2004.
 433. Watson S , Gallagher P , Smith MS , Young AH , Ferrier IN . Lithium, arginine vasopressin and the dex/CRH test in mood disordered patients. Psychoneuroendocrinology 32: 464‐469, 2007.
 434. Watson S , Gallagher P , Porter RJ , Smith MS , Herron LJ , Bulmer S , North East Mood Disorders Clinical Research Group, Young AH , Ferrier IN . A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biol Psychiatry 72: 943‐949, 2012.
 435. Watts AG , Sanchez‐Watts G . Region‐specific regulation of neuropeptide mRNAs in rat limbic forebrain neurones by aldosterone and corticosterone. J Physiol 484: 721‐736, 1995.
 436. Watts BV , Schnurr PP , Mayo L , Young‐Xu Y , Weeks WB , Friedman MJ . Meta‐analysis of the efficacy of treatments for posttraumatic stress disorder. J Clin Psychiatry 74: e541‐550, 2013.
 437. Webster MJ , Knable MB , O'Grady J , Orthmann J , Weickert CS . Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry 7: 985‐994, 2002.
 438. Wedekind D , Preiss B , Cohrs S , Ruether E , Huether G , Adler L . Relationship between nocturnal urinary cortisol excretion and symptom severity in subgroups of patients with depressive episodes. Neuropsychobiology 56: 119‐122, 2008.
 439. Weizman R , Gil‐Ad I , Hermesh H , Munitz H , Laron Z . Immunoreactive beta‐endorphin, cortisol, and growth hormone plasma levels in obsessive‐compulsive disorder. Clin Neuropharmacol 13: 297‐302, 1990.
 440. Wik G . Effects of neuroleptic treatment on cortisol and 3‐methoxy‐4‐hydroxyphenylethyl glycol levels in blood. J Endocrinol 144: 425‐429, 1995.
 441. Wolkowitz OM , Burke H , Epel ES , Reus VI . Glucocorticoids. Mood, memory, and mechanisms. Ann N Y Acad Sci 1179: 19‐40, 2009.
 442. Wong ML , Kling MA , Munson PJ , Listwak S , Licinio J , Prolo P , Karp B , McCutcheon IE , Geracioti TD, Jr , DeBellis MD , Rice KC , Goldstein DS , Veldhuis JD , Chrousos GP , Oldfield EH , McCann SM , Gold PW . Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: Relation to hypercortisolism and corticotropin‐releasing hormone. Proc Natl Acad Sci USA 97: 325‐330, 2000.
 443. Wyrwoll CS , Holmes MC , Seckl JR . 11β‐hydroxysteroid dehydrogenases and the brain: From zero to hero, a decade of progress. Front Neuroendocrinol 32: 265‐286, 2011.
 444. Xing GQ , Russell S , Webster MJ , Post RK . Decreased expression of mineralocorticoid receptor mRNA in the prefrontal cortex in schizophrenia and bipolar disorder. Int J Neuropsychopharmacol 7: 143‐153, 2004.
 445. Yau JLW , Noble J , Thomas S , Kerwin R , Morgan PE , Lightman S , Seckl JR , Pariante CM . The antidepressant desipramine requires the ABCB1 (Mdr1)‐type p‐glycoprotein to upregulate the glucocorticoid receptor in mice. Neuropsychopharmacology 32: 2520‐2529, 2007.
 446. Yehuda R , Teicher MH , Trestman RL , Levengood RA , Siever LJ . Cortisol regulation in posttraumatic stress disorder and major depression: A chronobiological analysis. Biol Psychiatry 40: 79‐88, 1996.
 447. Yehuda R . Risk and resilience in posttraumatic stress disorder. J Clin Psychiatry 65 (Suppl 1): 29‐36, 2004.
 448. Yehuda R , Yang RK , Golier JA , Grossman RA , Bierer LM , Tischler L . Effect of sertraline on glucocorticoid sensitivity of mononuclear leukocytes in post‐traumatic stress disorder. Neuropsychopharmacology 31: 189‐196, 2006.
 449. Yehuda R , LeDoux J . Response variation following trauma: A translational neuroscience approach to understanding PTSD. Neuron 56: 19‐32, 2007.
 450. Yehuda R . Status of glucocorticoid alterations in post‐traumatic stress disorder. Ann N Y Acad Sci 1179: 56‐69, 2009.
 451. Yehuda R , Bierer LM , Sarapas C , Makotkine I , Andrew R , Seckl JR . Cortisol metabolic predictors of response to psychotherapy for symptoms of PTSD in survivors of the World Trade Center attacks on September 11, 2001. Psychoneuroendocrinology 34: 1304‐1313, 2009.
 452. Yehuda R , Seckl J . Stress‐related psychiatric disorders with low cortisol levels: A metabolic hypothesis. Endocrinology 152: 4496‐4503, 2011.
 453. Young AH , Gallagher P , Watson S , Del‐Estal S , Owen BM , Ferrier IN . Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU‐486) in bipolar disorder. Neuropsychopharmacology 29: 1538‐1545, 2004.
 454. Young EA , Haskett RF , Grunhaus L , Pande A , Weinberg VM , Watson SJ , Akil H . Increased evening activation of the hypothalamic‐pituitary‐adrenal axis in depressed patients. Arch Gen Psychiatry 51: 701‐707, 1994.
 455. Young EA , Carlson NE , Brown MB . Twenty‐four hour ACTH and cortisol pulsatility in depressed women. Neuropsychopharmacology 25: 267‐276, 2001.
 456. Young EA , Abelson JL , Cameron OG . Effect of comorbid anxiety disorders on the hypothalamic‐pituitary‐adrenal axis response to a social stressor in major depression. Biol Psychiatry 56: 113‐120, 2004.
 457. Young EA , Veldhuis JD . Disordered adrenocorticotropin secretion in women with major depression. J Clin Endocrinol Metab 91: 1924‐1928, 2006.
 458. Young WS , Mezey E , Siegel RE . Vasopressin and oxytocin mRNAs in adrenalectomized and Brattleboro rats: Analysis by quantitative in situ hybridization histochemistry. Brain Research 387: 231‐241, 1986.
 459. Zarate CA , Manji HK . Bipolar disorder: Candidate drug targets. Mt Sinai J Med 75: 226‐247, 2008.
 460. Zhang W , Davidson JR . Post‐traumatic stress disorder: An evaluation of existing pharmacotherapies and new strategies. Expert Opin Pharmacother 8: 1861‐1870, 2007.
 461. Zhang XY , Zhou DF , Cao LY , Wu GY , Shen YC . Cortisol and cytokines in chronic and treatment‐resistant patients with schizophrenia: Association with psychopathology and response to antipsychotics. Neuropsychopharmacology 30: 1532‐1538, 2005.
 462. Zinke K , Fries E , Kliegel M , Kirschbaum C , Dettenborn L . Children with high‐functioning autism show a normal cortisol awakening response (CAR). Psychoneuroendocrinology 35: 1578‐1582, 2010.
 463. Zobel AW , Nickel T , Künzel HE , Ackl N , Sonntag A , Ising M , Holsboer F . Effects of the high‐affinity corticotropin‐releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated. J Psychiatric Res 34: 171‐181, 2000.
 464. Zobel AW , Nickel T , Sonntag A , Uhr M , Holsboer F , Ising M . Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study. J Psychiatr Res 35: 83‐94, 2001.
 465. Zofkova I , Hampl R . Influence of trifluoperazine on ACTH‐ or angiotensin‐stimulated mineralocorticoid and glucocorticoid secretion in man. Exp Clin Endocrinol 90: 93‐98, 1987.
 466. Zohar J , Yahalom H , Kozlovsky N , Cwikel‐Hamzany S , Matar MA , Kaplan Z , Yehuda R , Cohen H . High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: Interplay between clinical and animal studies. Eur Neuropsychopharmacol 21: 796‐809, 2011.

Related Articles:

Emotion
Schizophrenia: Nature of the Disease Process and its Biological Correlates
Brain Monoamines, Homeostasis, and Adaptive Behavior

Contact Editor

Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Hypothalamic‐Pituitary‐Adrenocortical Axis: Neuropsychiatric Aspects
 

How to Cite

Lauren Jacobson. Hypothalamic‐Pituitary‐Adrenocortical Axis: Neuropsychiatric Aspects. Compr Physiol 2014, 4: 715-738. doi: 10.1002/cphy.c130036